Thomas Jefferson University

Richard Goldberg

TitleVolunteer Faculty
InstitutionThomas Jefferson University
DepartmentFaculty Records and Publicatio - Thomas Jefferson University
Address833 Chestnut Street
Philadelphia PA 19023
vCardDownload vCard

    Collapse Research 
    Collapse research activities and funding
    R25CA116339     (BASCH, ETHAN M.)Jul 1, 2005 - Aug 31, 2018
    NIH
    Cancer Care Quality Research Training Program
    Role: Co-Principal Investigator
    K12CA120780     (KIM, WILLIAM Y.)Jul 1, 2006 - Jun 30, 2029
    NIH
    UNC Oncology K12
    Role: Co-Principal Investigator
    T32CA128590     (CAREY, LISA A)Sep 1, 2008 - Aug 31, 2013
    NIH
    Academic Training in Oncology at the University of North Carolina at Chapel Hill
    Role: Co-Principal Investigator
    U10CA180850     (VERSCHRAEGEN, CLAIRE F.)May 6, 2014 - Feb 28, 2019
    NIH
    OSU as Network Lead Academic Participating Site for the NCI NCTN
    Role: Co-Principal Investigator

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Holowatyj AN, Overman MJ, Votanopoulos KI, Lowy AM, Wagner P, Washington MK, Eng C, Foo WC, Goldberg RM, Hosseini M, Idrees K, Johnson DB, Shergill A, Ward E, Zachos NC, Shelton D. Defining a 'cells to society' research framework for appendiceal tumours. Nat Rev Cancer. 2025 Apr; 25(4):293-315. PMID: 39979656.
      Citations:    
    2. Mittal P, Battaglin F, Baca Y, Xiu J, Farrell A, Soni S, Lo JH, Torres-Gonzalez L, Algaze S, Jayachandran P, Ashouri K, Wong A, Zhang W, Yu J, Zhang L, Weinberg BA, Lou E, Shields AF, Goldberg RM, Marshall JL, Goel S, Singh IK, Lenz HJ. Comprehensive characterization of MCL-1 in patients with colorectal cancer: Expression, molecular profiles, and outcomes. Int J Cancer. 2025 Apr 15; 156(8):1583-1593. PMID: 39740007.
      Citations:    
    3. Bhutiani N, Hu CY, Palis B, Cotler J, Shi Q, Washington MK, Goldberg RM, Steele SR, Chang GJ. Lack of Hierarchical Survival Prognosis in AJCC Staging for Colon and Rectal Cancer-Implications for Future Summary Stage Classification. Clin Colorectal Cancer. 2024 Dec 04. PMID: 39730283.
      Citations:    
    4. Brown JC, Ma C, Shi Q, Couture F, Kuebler P, Kumar P, Tan B, Krishnamurthi S, Chang V, Goldberg RM, O'Reilly EM, Shields AF, Meyerhardt JA. Inflammation, physical activity, and disease-free survival in stage III colon cancer: Cancer and Leukemia Group B-Southwest Oncology Group 80702 (Alliance). J Natl Cancer Inst. 2024 Dec 01; 116(12):2032-2039. PMID: 39180477.
      Citations:    
    5. Arai H, Gandhi N, Battaglin F, Wang J, Algaze S, Jayachandran P, Soni S, Zhang W, Yang Y, Millstein J, Lo JH, Sohal D, Goldberg R, Hall MJ, Scott AJ, Hwang JJ, Lou E, Weinberg BA, Marshall J, Goel S, Xiu J, Korn WM, Lenz HJ. Role of CD47 gene expression in colorectal cancer: a comprehensive molecular profiling study. J Immunother Cancer. 2024 Nov 05; 12(11). PMID: 39500526.
      Citations:    
    6. Wang J, Xiu J, Battaglin F, Arai H, Soni S, Zhang W, Goldberg RM, Philip PA, Seeber A, Hwang JJ, Shields AF, Marshall JL, Astaturov I, Liu T, Lockhart AC, Korn WM, Shen L, Lenz HJ. Large-scale analysis of CDH1 mutations defines a distinctive molecular subset with treatment implications in gastric cancer. NPJ Precis Oncol. 2024 Sep 30; 8(1):214. PMID: 39349771.
      Citations:    
    7. Phalen P, Jones N, Davis B, Sarpal D, Dickerson F, Vatza C, Jumper M, Kuczynski A, Thompson E, Jay S, Buchanan R, Chengappa KNR, Goldberg R, Kreyenbuhl J, Margolis R, Dong F, Riggs J, Moxam A, Burris E, Campbell P, Cooke A, Ered A, Fauble M, Howell C, Kelly C, Namowicz D, Rouse K, Smith W, Wolcott M, Boumaiz Y, Harvin A, Scheinberg R, Saravana A, Nayar S, Kohler C, Calkins ME, Bennett M. Suicidality among clients in a network of coordinated specialty care (CSC) programs for first-episode psychosis: Rates, changes in rates, and their predictors. Schizophr Res. 2024 12; 274:150-157. PMID: 39298811.
      Citations:    
    8. Chibaudel B, Raeisi M, Cohen R, Yothers G, Goldberg RM, Bachet JB, Wolmark N, Yoshino T, Schmoll HJ, Kerr R, Lonardi S, George TJ, Shacham-Shmueli E, Shi Q, Andr? T, de Gramont A. Assessment of the Addition of Oxaliplatin to Fluoropyrimidine-Based Adjuvant Chemotherapy in Patients With High-Risk Stage II Colon Cancer: An ACCENT Pooled Analysis. J Clin Oncol. 2024 Dec 10; 42(35):4187-4195. PMID: 39231393.
      Citations:    
    9. Malla M, Deshmukh SK, Wu S, Samec T, Olevian DC, El Naili R, El-Rayes B, Xiu J, Farrell A, Lenz HJ, Lou E, Goel S, Spetzler D, Goldberg RM, Hazlehurst L. Mesothelin expression correlates with elevated inhibitory immune activity in patients with colorectal cancer. Cancer Gene Ther. 2024 Oct; 31(10):1547-1558. PMID: 39174744.
      Citations:    
    10. Cohen R, Raeisi M, Chibaudel B, Shi Q, Yoshino T, Zalcberg JR, Adams R, Cremolini C, Van Cutsem E, Heinemann V, Tabernero J, Punt CJA, Arnold D, Hurwitz HI, Douillard JY, Venook AP, Saltz LB, Maughan TS, Kabbinavar F, Bokemeyer C, Grothey A, Mayer RJ, Kaplan R, Tebbutt NC, Randolph Hecht J, Giantonio BJ, D?az-Rubio E, Sobrero AF, Peeters M, Koopman M, Goldberg RM, Andre T, de Gramont A. Prognostic value of liver metastases in colorectal cancer treated by systemic therapy: An ARCAD pooled analysis. Eur J Cancer. 2024 Aug; 207:114160. PMID: 38896997.
      Citations:    
    11. Taieb J, Basile D, Seligmann J, Argiles G, Andr? T, Gallois C, Goldberg RM, Yothers G, Sobrero A, Meyerhardt JA, Souglakos J, Labianca R, Iveson T, Church DN, Arnold D, Tie J, Gill S, Laurent-Puig P, Yoshino T, Lonardi S, Shi Q. Standardizing data collection in adjuvant colon cancer trials: A consensus project from the IDEA and ACCENT international consortia and national experts. Eur J Cancer. 2024 Jul; 206:114118. PMID: 38810317.
      Citations:    
    12. Ranney RM, Goldberg R, Maguen S, Blonigen D. Peer specialist-led interventions in primary care at the Veterans Health Administration: An integrative review. Psychol Serv. 2024 Apr 11. PMID: 38602826.
      Citations:    
    13. Gallois C, Shi Q, Pederson LD, Andr? T, Iveson TJ, Sobrero AF, Alberts S, de Gramont A, Meyerhardt JA, George T, Schmoll HE, Souglakos I, Harkin A, Labianca R, Sinicrope FA, Oki E, Shields AF, Boukovinas I, Kerr R, Lonardi S, Yothers G, Yoshino T, Goldberg RM, Taieb J, Papamichael D. Oxaliplatin-Based Adjuvant Chemotherapy in Older Patients With Stage III Colon Cancer: An ACCENT/IDEA Pooled Analysis of 12 Trials. J Clin Oncol. 2024 Jul 01; 42(19):2295-2305. PMID: 38547438.
      Citations:    
    14. Battaglin F, Ou FS, Qu X, Hochster HS, Niedzwiecki D, Goldberg RM, Mayer RJ, Ashouri K, Zemla TJ, Blanke CD, Venook AP, Kabbarah O, Lenz HJ, Innocenti F. HER2 Gene Expression Levels Are Predictive and Prognostic in Patients With Metastatic Colorectal Cancer Enrolled in CALGB/SWOG 80405. J Clin Oncol. 2024 Jun 01; 42(16):1890-1902. PMID: 38457761.
      Citations:    
    15. Arai H, Yang Y, Baca Y, Millstein J, Denda T, Ou FS, Innocenti F, Takeda H, Kubota Y, Doi A, Horie Y, Umemoto K, Izawa N, Wang J, Battaglin F, Jayachandran P, Algaze S, Soni S, Zhang W, Goldberg RM, Hall MJ, Scott AJ, Hwang JJ, Lou E, Weinberg BA, Marshall J, Goel S, Xiu J, Michael Korn W, Venook AP, Sunakawa Y, Lenz HJ. Predictive value of CDC37 gene expression for targeted therapy in metastatic colorectal cancer. Eur J Cancer. 2024 Apr; 201:113914. PMID: 38359495.
      Citations:    
    16. Battaglin F, Baca Y, Millstein J, Yang Y, Xiu J, Arai H, Wang J, Ou FS, Innocenti F, Mumenthaler SM, Jayachandran P, Kawanishi N, Lenz A, Soni S, Algaze S, Zhang W, Khoukaz T, Roussos Torres E, Seeber A, Abraham JP, Lou E, Philip PA, Weinberg BA, Shields AF, Goldberg RM, Marshall JL, Venook AP, Korn WM, Lenz HJ. CCR5 and CCL5 gene expression in colorectal cancer: comprehensive profiling and clinical value. J Immunother Cancer. 2024 01 11; 12(1). PMID: 38212126.
      Citations:    
    17. Malla M, Kumar Deshkmukh S, Wu S, Samec T, Olevian D, Naili R, Bassel ER, Xiu J, Farrell A, Lenz HJ, Lou E, Goel S, Spetzler D, Goldberg RM, Hazlehurst L. Mesothelin expression correlates with elevated inhibitory immune activity in patients with colorectal cancer. Res Sq. 2023 Dec 28. PMID: 38234761.
      Citations:    
    18. Janczewski LM, Browner A, Cotler J, Nelson H, Ballman KV, LeBlanc M, Gollub MJ, Eng C, Brierley JD, Palefsky JM, Goldberg RM, Goodman KA, Washington MK, Asare EA, Palis B. Data-driven optimization of version 9 American Joint Committee on Cancer staging system for anal cancer. Cancer. 2024 May 01; 130(9):1702-1710. PMID: 38140735.
      Citations:    
    19. Brown JC, Ma C, Shi Q, Zemla T, Couture F, Kuebler P, Kumar P, Tan B, Krishnamurthi S, Chang V, Goldberg RM, Venook AP, Blanke CD, O'Reilly EM, Shields AF, Meyerhardt JA. Physical activity in recurrent colon cancer: Cancer and Leukemia Group B/SWOG 80702 (Alliance). Cancer. 2023 12 01; 129(23):3724-3734. PMID: 37651160.
      Citations:    
    20. Ou FS, Ahn DH, Dixon JG, Grothey A, Lou Y, Kasi PM, Hubbard JM, Van Cutsem E, Saltz LB, Schmoll HJ, Goldberg RM, Venook AP, Hoff P, Douillard JY, Hecht JR, Hurwitz H, Punt CJA, Koopman M, Bokemeyer C, Fuchs CS, Diaz-Rubio E, Tebbutt NC, Cremolini C, Kabbinavar FF, Bekaii-Saab T, Chibaudel B, Yoshino T, Zalcberg J, Adams RA, de Gramont A, Shi Q. Evaluation of Intratumoral Response Heterogeneity in Metastatic Colorectal Cancer and Its Impact on Patient Overall Survival: Findings from 10,551 Patients in the ARCAD Database. Cancers (Basel). 2023 Aug 15; 15(16). PMID: 37627145.
      Citations:    
    21. Park HA, Edelmann D, Canzian F, Seibold P, Harrison TA, Hua X, Shi Q, Silverman A, Benner A, Macauda A, Schneider M, Goldberg RM, Alberts SR, Hoffmeister M, Brenner H, Chan AT, Peters U, Newcomb PA, Chang-Claude J. Genome-wide study of genetic polymorphisms predictive for outcome from first-line oxaliplatin-based chemotherapy in colorectal cancer patients. Int J Cancer. 2023 11 01; 153(9):1623-1634. PMID: 37539667.
      Citations:    
    22. Wang QL, Ma C, Yuan C, Shi Q, Wolpin BM, Zhang Y, Fuchs CS, Meyer J, Zemla T, Cheng E, Kumthekar P, Guthrie KA, Couture F, Kuebler P, Kumar P, Tan B, Krishnamurthi S, Goldberg RM, Venook A, Blanke C, Shields AF, O'Reilly EM, Meyerhardt JA, Ng K. Plasma 25-Hydroxyvitamin D Levels and Survival in Stage III Colon Cancer: Findings from CALGB/SWOG 80702 (Alliance). Clin Cancer Res. 2023 07 14; 29(14):2621-2630. PMID: 37289007.
      Citations:    
    23. Goldberg RM, Sargent DJ, Morton RF, Fuchs CS, Ramanathan RK, Williamson SK, Findlay BP, Pitot HC, Alberts SR. A Randomized Controlled Trial of Fluorouracil Plus Leucovorin, Irinotecan, and Oxaliplatin Combinations in Patients With Previously Untreated Metastatic Colorectal Cancer. J Clin Oncol. 2023 07 01; 41(19):3461-3468. PMID: 37379691.
      Citations:    
    24. Janczewski LM, Browner AE, Cotler JH, Nelson H, Kakar S, Carr NJ, Hanna NN, Holowatyj AN, Goldberg RM, Washington MK, Asare EA, Overman MJ. Survival outcomes used to validate version 9 of the American Joint Committee on Cancer staging system for appendiceal cancer. CA Cancer J Clin. 2023 Nov-Dec; 73(6):590-596. PMID: 37358310.
      Citations:    
    25. Janczewski LM, Faski J, Nelson H, Gollub MJ, Eng C, Brierley JD, Palefsky JM, Goldberg RM, Washington MK, Asare EA, Goodman KA. Survival outcomes used to generate version 9 American Joint Committee on Cancer staging system for anal cancer. CA Cancer J Clin. 2023 Sep-Oct; 73(5):516-523. PMID: 37114458.
      Citations:    
    26. Malla M, Fekrmandi F, Malik N, Hatoum H, George S, Goldberg RM, Mukherjee S. The evolving role of radiation in pancreatic cancer. Front Oncol. 2022; 12:1060885. PMID: 36713520.
      Citations:    
    27. McGarrah P, Hubbard J, Novotny PJ, Branda ME, Sargent DS, Morton RF, Fuchs CS, Benson AB, Williamson SK, Findlay BP, Alberts SR, Goldberg RM, Sloan JA. Baseline Quality of Life is a Strong and Independent Prognostic Factor for Overall Survival in Metastatic Colorectal Cancer. Cancer Control. 2023 Jan-Dec; 30:10732748231185047. PMID: 37339926.
      Citations:    
    28. Kocher F, Puccini A, Untergasser G, Martowicz A, Zimmer K, Pircher A, Baca Y, Xiu J, Haybaeck J, Tymoszuk P, Goldberg RM, Petrillo A, Shields AF, Salem ME, Marshall JL, Hall M, Korn WM, Nabhan C, Battaglin F, Lenz HJ, Lou E, Choo SP, Toh CK, Gasteiger S, Pichler R, Wolf D, Seeber A. Multi-omic Characterization of Pancreatic Ductal Adenocarcinoma Relates CXCR4 mRNA Expression Levels to Potential Clinical Targets. Clin Cancer Res. 2022 11 14; 28(22):4957-4967. PMID: 36112544.
      Citations:    
    29. Lee S, Ma C, Shi Q, Kumar P, Couture F, Kuebler P, Krishnamurthi S, Lewis D, Tan B, Goldberg RM, Venook A, Blanke C, O'Reilly EM, Shields AF, Meyerhardt JA. Potential Mediators of Oxaliplatin-Induced Peripheral Neuropathy From Adjuvant Therapy in Stage III Colon Cancer: Findings From CALGB (Alliance)/SWOG 80702. J Clin Oncol. 2023 02 10; 41(5):1079-1091. PMID: 36367997.
      Citations:    
    30. Park HA, Edelmann D, Canzian F, Harrison TA, Hua X, Shi Q, Silverman A, Schneider M, Goldberg RM, Alberts SR, Hoffmeister M, Brenner H, Chan AT, Peters U, Newcomb PA, Chang-Claude J. Predictive Polygenic Score for Outcome after First-Line Oxaliplatin-Based Chemotherapy in Colorectal Cancer Patients Using Supervised Principal Component Analysis. Cancer Epidemiol Biomarkers Prev. 2022 11 02; 31(11):2087-2091. PMID: 35984985.
      Citations:    
    31. Gallois C, Shi Q, Meyers JP, Iveson T, Alberts SR, de Gramont A, Sobrero AF, Haller DG, Oki E, Shields AF, Goldberg RM, Kerr R, Lonardi S, Yothers G, Kelly C, Boukovinas I, Labianca R, Sinicrope FA, Souglakos I, Yoshino T, Meyerhardt JA, Andr? T, Papamichael D, Taieb J. Prognostic Impact of Early Treatment and Oxaliplatin Discontinuation in Patients With Stage III Colon Cancer: An ACCENT/IDEA Pooled Analysis of 11 Adjuvant Trials. J Clin Oncol. 2023 02 01; 41(4):803-815. PMID: 36306483.
      Citations:    
    32. Malla M, Fuqua J, Mukherjee S, Goldberg RM. Optimal First-Line Therapy for Metastatic Adenocarcinoma of the Esophagus. Curr Treat Options Oncol. 2022 12; 23(12):1748-1760. PMID: 36272049.
      Citations:    
    33. Argil?s G, Mulet N, Valladares-Ayerbes M, Vi?itez JM, Gr?valos C, Garc?a-Alfonso P, Santos C, Tobe?a M, Garc?a-Paredes B, Benavides M, Cano MT, Loupakis F, Rodr?guez-Garrote M, Rivera F, Goldberg RM, Cremolini C, Bennouna J, Ciardiello F, Tabernero JM, Aranda E, Argil?s G, Tabernero J. A randomised phase 2 study comparing different dose approaches of induction treatment of regorafenib?in previously treated metastatic colorectal cancer patients (REARRANGE trial). Eur J Cancer. 2022 12; 177:154-163. PMID: 36335783.
      Citations:    
    34. Peeples AD, Muralidharan A, McCarthy S, Goldberg R, Kuykendall L, Vineyard N, Chinman M. Barriers and Enablers to Implementing Peer Specialists in Veterans Health Administration Primary Care: a Qualitative Study. J Gen Intern Med. 2023 02; 38(3):707-714. PMID: 36127539.
      Citations:    
    35. Van Blarigan EL, Ma C, Ou FS, Bainter TM, Venook AP, Ng K, Niedzwiecki D, Giovannucci E, Lenz HJ, Polite BN, Hochster HS, Goldberg RM, Mayer RJ, Blanke CD, O'Reilly EM, Ciombor KK, Meyerhardt JA. Dietary fat in relation to all-cause mortality and cancer progression and death among people with metastatic colorectal cancer: Data from CALGB 80405 (Alliance)/SWOG 80405. Int J Cancer. 2023 01 15; 152(2):123-136. PMID: 35904874.
      Citations:    
    36. Franko J, Yin J, Adams RA, Zalcberg J, Fiskum J, Van Cutsem E, Goldberg RM, Hurwitz H, Bokemeyer C, Kabbinavar F, Curtis A, Meyers J, Chibaudel B, Yoshino T, de Gramont A, Shi Q. Trajectories of body weight change and survival among patients with mCRC treated with systemic therapy: Pooled analysis from the ARCAD database. Eur J Cancer. 2022 10; 174:142-152. PMID: 35994794.
      Citations:    
    37. Sinicrope FA, Shi Q, Catteau A, Poage GM, Zemla TJ, Mlecnik B, Benson AB, Gill S, Goldberg RM, Kahlenberg MS, Nair SG, Shields AF, Smyrk TC, Galon J, Alberts SR. Immunoscore Is Prognostic in Low-Risk and High-Risk Stage III Colon Carcinomas Treated With Adjuvant Infusional Fluorouracil, Leucovorin, and Oxaliplatin in a Phase III Trial. JCO Precis Oncol. 2022 08; 6:e2200010. PMID: 35952316.
      Citations:    
    38. Goldberg RM, Adams R, Buyse M, Eng C, Grothey A, Andr? T, Sobrero AF, Lichtman SM, Benson AB, Punt CJA, Maughan T, Burzykowski T, Sommeijer D, Saad ED, Shi Q, Coart E, Chibaudel B, Koopman M, Schmoll HJ, Yoshino T, Taieb J, Tebbutt NC, Zalcberg J, Tabernero J, Van Cutsem E, Matheson A, de Gramont A. Clinical Trial Endpoints in Metastatic Cancer: Using Individual Participant Data to Inform Future Trials Methodology. J Natl Cancer Inst. 2022 06 13; 114(6):819-828. PMID: 34865086.
      Citations:    
    39. Puccini A, Poorman K, Catalano F, Seeber A, Goldberg RM, Salem ME, Shields AF, Berger MD, Battaglin F, Tokunaga R, Naseem M, Zhang W, Philip PA, Marshall JL, Korn WM, Lenz HJ. Molecular profiling of signet-ring-cell carcinoma (SRCC) from the stomach and colon reveals potential new therapeutic targets. Oncogene. 2022 06; 41(26):3455-3460. PMID: 35618879.
      Citations:    
    40. Seeber A, Battaglin F, Zimmer K, Kocher F, Baca Y, Xiu J, Spizzo G, Novotny-Diermayr V, Rieder D, Puccini A, Swensen J, Ellis M, Goldberg RM, Grothey A, Shields AF, Marshall JL, Weinberg BA, Sackstein PE, Lim KH, Tan GS, Nabhan C, Korn WM, Amann A, Trajanoski Z, Berger MD, Lou E, Wolf D, Lenz HJ. Comprehensive Analysis of R-Spondin Fusions and RNF43 Mutations Implicate Novel Therapeutic Options in Colorectal Cancer. Clin Cancer Res. 2022 05 02; 28(9):1863-1870. PMID: 35254413.
      Citations:    
    41. Heinlein E, Taylor J, Goldberg R, Potts W, RachBeisel J, Medoff D, Li L, Himelhoch S. Impact of a Targeted Intervention on Hepatitis C Care Among African Americans With Serious Mental Illness. Psychiatr Serv. 2022 11 01; 73(11):1278-1281. PMID: 35473365.
      Citations:    
    42. Christou N, Bergen ES, Canton C, Le Malicot K, Di Bartolomeo M, Galli F, Galli F, Labianca R, Shi Q, Alberts SR, Goldberg RM, Lepage C, Sinicrope FA, Taieb J. Impact of diabetes and metformin use on recurrence and outcome in stage II-III colon cancer patients-A pooled analysis of three adjuvant trials. Eur J Cancer. 2022 May; 166:100-111. PMID: 35279470.
      Citations:    
    43. Lipsyc-Sharf M, Zhang S, Ou FS, Ma C, McCleary NJ, Niedzwiecki D, Chang IW, Lenz HJ, Blanke CD, Piawah S, Van Loon K, Bainter TM, Venook AP, Mayer RJ, Fuchs CS, Innocenti F, Nixon AB, Goldberg R, O'Reilly EM, Meyerhardt JA, Ng K. Survival in Young-Onset Metastatic Colorectal Cancer: Findings From Cancer and Leukemia Group B (Alliance)/SWOG 80405. J Natl Cancer Inst. 2022 03 08; 114(3):427-435. PMID: 34636852.
      Citations:    
    44. McCleary NJ, Harmsen WS, Haakenstad E, Cleary JM, Meyerhardt JA, Zalcberg J, Adams R, Grothey A, Sobrero AF, Van Cutsem E, Goldberg RM, Peeters M, Tabernero J, Seymour M, Saltz LB, Giantonio BJ, Arnold D, Rothenberg ML, Koopman M, Schmoll HJ, Pitot HC, Hoff PM, Tebbutt N, Masi G, Souglakos J, Bokemeyer C, Heinemann V, Yoshino T, Chibaudel B, deGramont A, Shi Q, Lichtman SM. Metastatic Colorectal Cancer Outcomes by Age Among ARCAD First- and Second-Line Clinical Trials. JNCI Cancer Spectr. 2022 03 02; 6(2). PMID: 35603849.
      Citations:    
    45. McCleary NJ, Zhang S, Ma C, Ou FS, Bainter TM, Venook AP, Niedzwiecki D, Lenz HJ, Innocenti F, O'Neil BH, Polite BN, Hochster HS, Atkins JN, Goldberg RM, Ng K, Mayer RJ, Blanke CD, O'Reilly EM, Fuchs CS, Meyerhardt JA. Age and comorbidity association with survival outcomes in metastatic colorectal cancer: CALGB 80405 analysis. J Geriatr Oncol. 2022 05; 13(4):469-479. PMID: 35105521.
      Citations:    
    46. Jin Z, Dixon JG, Fiskum JM, Parekh HD, Sinicrope FA, Yothers G, Allegra CJ, Wolmark N, Haller D, Schmoll HJ, de Gramont A, Kerr R, Taieb J, Van Cutsem E, Tweleves C, O'Connell M, Saltz LB, Sadahiro S, Blanke CD, Tomita N, Seitz JF, Erlichman C, Yoshino T, Yamanaka T, Marsoni S, Andre T, Mahipal A, Goldberg RM, George TJ, Shi Q. Clinicopathological and Molecular Characteristics of Early-Onset Stage III Colon Adenocarcinoma: An Analysis of the ACCENT Database. J Natl Cancer Inst. 2021 11 29; 113(12):1693-1704. PMID: 34405233.
      Citations:    
    47. Arai H, Elliott A, Millstein J, Xiu J, Ou FS, Innocenti F, Wang J, Battaglin F, Jayachandran P, Kawanishi N, Soni S, Zhang W, Sohal D, Goldberg RM, Hall MJ, Scott AJ, Khushman M, Hwang JJ, Lou E, Weinberg BA, Lockhart AC, Shields AF, Abraham JP, Magee D, Stafford P, Zhang J, Venook AP, Korn WM, Lenz HJ. Molecular characteristics and clinical outcomes of patients with Neurofibromin 1-altered metastatic colorectal cancer. Oncogene. 2022 01; 41(2):260-267. PMID: 34728807.
      Citations:    
    48. Cerniglia M, Xiu J, Grothey A, Pishvaian MJ, Baca Y, Hwang JJ, Marshall JL, VanderWalde AM, Shields AF, Lenz HJ, Korn WM, Salem M, Philip PA, Goldberg RM, Zeng J, Kim SS. Association of Homologous Recombination-DNA Damage Response Gene Mutations with Immune Biomarkers in Gastroesophageal Cancers. Mol Cancer Ther. 2022 01; 21(1):227-236. PMID: 34725190.
      Citations:    
    49. Puccini A, Seeber A, Xiu J, Goldberg RM, Soldato D, Grothey A, Shields AF, Salem ME, Battaglin F, Berger MD, El-Deiry WS, Tokunaga R, Naseem M, Zhang W, Arora SP, Khushman MM, Hall MJ, Philip PA, Marshall JL, Korn WM, Lenz HJ. Molecular differences between lymph nodes and distant metastases compared with primaries in colorectal cancer patients. NPJ Precis Oncol. 2021 Oct 27; 5(1):95. PMID: 34707195.
      Citations:    
    50. Masab M, Gross A, Flanagan M, Goldberg R, Malla M. Neuroendocrine Neoplasm of the Breast Presenting as a Liver Metastasis: A Rare Diagnostic Challenge. Cureus. 2021 Aug; 13(8):e16860. PMID: 34513437.
      Citations:    
    51. Sinicrope FA, Shi Q, Smyrk TC, Goldberg RM, Cohen SJ, Gill S, Kahlenberg MS, Nair S, Shield AF, Jahagirdar BN, Jacobson SB, Foster NR, Pollak MN, Alberts SR. Association of Adiponectin and Vitamin D With Tumor Infiltrating Lymphocytes and Survival in Stage III Colon Cancer. JNCI Cancer Spectr. 2021 10; 5(5). PMID: 34485815.
      Citations:    
    52. Yin J, Dawood S, Cohen R, Meyers J, Zalcberg J, Yoshino T, Seymour M, Maughan T, Saltz L, Van Cutsem E, Venook A, Schmoll HJ, Goldberg R, Hoff P, Hecht JR, Hurwitz H, Punt C, Diaz Rubio E, Koopman M, Cremolini C, Heinemann V, Tournigard C, Bokemeyer C, Fuchs C, Tebbutt N, Souglakos J, Doulliard JY, Kabbinavar F, Chibaudel B, de Gramont A, Shi Q, Grothey A, Adams R. Impact of geography on prognostic outcomes of 21,509 patients with metastatic colorectal cancer enrolled in clinical trials: an ARCAD database analysis. Ther Adv Med Oncol. 2021; 13:17588359211020547. PMID: 34262614.
      Citations:    
    53. Wang J, Xiu J, Baca Y, Battaglin F, Arai H, Kawanishi N, Soni S, Zhang W, Millstein J, Salhia B, Goldberg RM, Philip PA, Seeber A, Hwang JJ, Shields AF, Marshall JL, Astsaturov I, Craig Lockhart A, Gatalica Z, Michael Korn W, Lenz HJ. Large-scale analysis of KMT2 mutations defines a distinctive molecular subset with treatment implication in gastric cancer. Oncogene. 2021 07; 40(30):4894-4905. PMID: 34163031.
      Citations:    
    54. Chinman M, Goldberg R, Daniels K, Muralidharan A, Smith J, McCarthy S, Medoff D, Peeples A, Kuykendall L, Vineyard N, Li L. Implementation of peer specialist services in VA primary care: a cluster randomized trial on the impact of external facilitation. Implement Sci. 2021 06 07; 16(1):60. PMID: 34099004.
      Citations:    
    55. Hua X, Dai JY, Lindstr?m S, Harrison TA, Lin Y, Alberts SR, Alwers E, Berndt SI, Brenner H, Buchanan DD, Campbell PT, Casey G, Chang-Claude J, Gallinger S, Giles GG, Goldberg RM, Gunter MJ, Hoffmeister M, Jenkins MA, Joshi AD, Ma W, Milne RL, Murphy N, Pai RK, Sakoda LC, Schoen RE, Shi Q, Slattery ML, Song M, White E, Marchand LL, Chan AT, Peters U, Newcomb PA. Genetically Predicted Circulating C-Reactive Protein Concentration and Colorectal Cancer Survival: A Mendelian Randomization Consortium Study. Cancer Epidemiol Biomarkers Prev. 2021 07; 30(7):1349-1358. PMID: 33972368.
      Citations:    
    56. Pearlman R, Frankel WL, Swanson BJ, Jones D, Zhao W, Yilmaz A, Miller K, Bacher J, Bigley C, Nelsen L, Goodfellow PJ, Goldberg RM, Paskett E, Shields PG, Freudenheim JL, Stanich PP, Lattimer I, Arnold M, Prior TW, Haut M, Kalady MF, Heald B, Paquette I, Draper DJ, Brell JM, Mahesh S, Weeman K, Bastola S, Zangmeister J, Gowda A, Kencana F, Malcolm A, Liu Y, Cole S, Bane C, Li C, Rehmus E, Pritchard CC, Shirts BH, Jacobson A, Cummings SA, de la Chapelle A, Hampel H. Prospective Statewide Study of Universal Screening for Hereditary Colorectal Cancer: The Ohio Colorectal Cancer Prevention Initiative. JCO Precis Oncol. 2021; 5. PMID: 34250417.
      Citations:    
    57. Meyerhardt JA, Shi Q, Fuchs CS, Meyer J, Niedzwiecki D, Zemla T, Kumthekar P, Guthrie KA, Couture F, Kuebler P, Bendell JC, Kumar P, Lewis D, Tan B, Bertagnolli M, Grothey A, Hochster HS, Goldberg RM, Venook A, Blanke C, O'Reilly EM, Shields AF. Effect of Celecoxib vs Placebo Added to Standard Adjuvant Therapy on Disease-Free Survival Among Patients With Stage III Colon Cancer: The CALGB/SWOG 80702 (Alliance) Randomized Clinical Trial. JAMA. 2021 04 06; 325(13):1277-1286. PMID: 33821899.
      Citations:    
    58. Wagner AD, Grothey A, Andre T, Dixon JG, Wolmark N, Haller DG, Allegra CJ, de Gramont A, VanCutsem E, Alberts SR, George TJ, O'Connell MJ, Twelves C, Taieb J, Saltz LB, Blanke CD, Francini E, Kerr R, Yothers G, Seitz JF, Marsoni S, Goldberg RM, Shi Q. Sex and Adverse Events of Adjuvant Chemotherapy in Colon Cancer: An Analysis of 34?640 Patients in the ACCENT Database. J Natl Cancer Inst. 2021 04 06; 113(4):400-407. PMID: 32835356.
      Citations:    
    59. Arai H, Elliott A, Xiu J, Wang J, Battaglin F, Kawanishi N, Soni S, Zhang W, Millstein J, Sohal D, Goldberg RM, Hall MJ, Scott AJ, Khushman M, Hwang JJ, Lou E, Weinberg BA, Marshall JL, Lockhart AC, Stafford P, Zhang J, Moretto R, Cremolini C, Korn WM, Lenz HJ. The Landscape of Alterations in DNA Damage Response Pathways in Colorectal Cancer. Clin Cancer Res. 2021 06 01; 27(11):3234-3242. PMID: 33766816.
      Citations:    
    60. Holcombe RF, Verschraegen CF, Chapman AE, Gaffney D, Goldberg RM, Mesa RA, Milhem M, Mims M, Mitchell EP, Mulkerin D, Vijayakumar S. Status of the Clinician Investigator in America: An Essential Healthcare Provider Driving Advances in Cancer Care. J Natl Compr Canc Netw. 2021 02; 19(2):122-125. PMID: 33545684.
      Citations:    
    61. Cohen R, Taieb J, Fiskum J, Yothers G, Goldberg R, Yoshino T, Alberts S, Allegra C, de Gramont A, Seitz JF, O'Connell M, Haller D, Wolmark N, Erlichman C, Zaniboni A, Lonardi S, Kerr R, Grothey A, Sinicrope FA, Andr? T, Shi Q. Microsatellite Instability in Patients With Stage III Colon Cancer Receiving Fluoropyrimidine With or Without Oxaliplatin: An ACCENT Pooled Analysis of 12 Adjuvant Trials. J Clin Oncol. 2021 02 20; 39(6):642-651. PMID: 33356421.
      Citations:    
    62. Sinicrope FA, Chakrabarti S, Laurent-Puig P, Huebner L, Smyrk TC, Tabernero J, Mini E, Goldberg RM, Zaanan A, Folprecht G, Van Laethem JL, Le Malicot K, Shi Q, Alberts SR, Taieb J. Prognostic variables in low and high risk stage III colon cancers treated in two adjuvant chemotherapy trials. Eur J Cancer. 2021 02; 144:101-112. PMID: 33341444.
      Citations:    
    63. Washington MK, Goldberg RM, Chang GJ, Limburg P, Lam AK, Salto-Tellez M, Arends MJ, Nagtegaal ID, Klimstra DS, Rugge M, Schirmacher P, Lazar AJ, Odze RD, Carneiro F, Fukayama M, Cree IA. Diagnosis of digestive system tumours. Int J Cancer. 2021 03 01; 148(5):1040-1050. PMID: 32674220.
      Citations:    
    64. Labadie JD, Hua X, Harrison TA, Banbury BL, Huyghe JR, Sun W, Shi Q, Yothers G, Alberts SR, Sinicrope FA, Goldberg RM, George TJ, Penney KL, Phipps AI, Cohen SA, Peters U, Chan AT, Newcomb PA. Genetic Predictors of Severe Skin Toxicity in Patients with Stage III Colon Cancer Treated with Cetuximab: NCCTG N0147 (Alliance). Cancer Epidemiol Biomarkers Prev. 2021 02; 30(2):404-411. PMID: 33203692.
      Citations:    
    65. Seeber A, Zimmer K, Kocher F, Puccini A, Xiu J, Nabhan C, Elliott A, Goldberg RM, Grothey A, Shields AF, Battaglin F, El-Deiry WS, Philip PA, Marshall JL, Hall M, Korn WM, Lenz HJ, Wolf D, Feistritzer C, Spizzo G. Molecular characteristics of BRCA1/2 and PALB2 mutations in pancreatic ductal adenocarcinoma. ESMO Open. 2020 11; 5(6):e000942. PMID: 33229504.
      Citations:    
    66. Mackintosh C, Yuan C, Ou FS, Zhang S, Niedzwiecki D, Chang IW, O'Neil BH, Mullen BC, Lenz HJ, Blanke CD, Venook AP, Mayer RJ, Fuchs CS, Innocenti F, Nixon AB, Goldberg RM, O'Reilly EM, Meyerhardt JA, Ng K. Association of Coffee Intake With Survival in Patients With Advanced or Metastatic Colorectal Cancer. JAMA Oncol. 2020 Nov 01; 6(11):1713-1721. PMID: 32940631.
      Citations:    
    67. Tokunaga R, Xiu J, Goldberg RM, Philip PA, Seeber A, Battaglin F, Arai H, Lo JH, Naseem M, Puccini A, Berger MD, Soni S, Zhang W, Chen S, Hwang JJ, Shields AF, Marshall JL, Baba H, Korn WM, Lenz HJ. The impact of ARID1A mutation on molecular characteristics in colorectal cancer. Eur J Cancer. 2020 11; 140:119-129. PMID: 33080474.
      Citations:    
    68. Arai H, Baca Y, Battaglin F, Kawanishi N, Wang J, Soni S, Zhang W, Millstein J, Johnston C, Goldberg RM, Philip PA, Seeber A, Xiu J, Hwang JJ, Shields AF, Marshall JL, Korn WM, Lenz HJ. Molecular Characterization of Appendiceal Goblet Cell Carcinoid. Mol Cancer Ther. 2020 12; 19(12):2634-2640. PMID: 33037134.
      Citations:    
    69. Lopes GS, Tournigand C, Olswold CL, Cohen R, Kempf E, Saltz L, Goldberg RM, Hurwitz H, Fuchs C, de Gramont A, Shi Q. Adverse event load, onset, and maximum grade: A novel method of reporting adverse events in cancer clinical trials. Clin Trials. 2021 02; 18(1):51-60. PMID: 32998522.
      Citations:    
    70. Van Blarigan EL, Zhang S, Ou FS, Venlo A, Ng K, Atreya C, Van Loon K, Niedzwiecki D, Giovannucci E, Wolfe EG, Lenz HJ, Innocenti F, O'Neil BH, Shaw JE, Polite BN, Hochster HS, Atkins JN, Goldberg RM, Mayer RJ, Blanke CD, O'Reilly EM, Fuchs CS, Meyerhardt JA. Association of Diet Quality With Survival Among People With Metastatic Colorectal Cancer in the Cancer and Leukemia B and Southwest Oncology Group 80405 Trial. JAMA Netw Open. 2020 10 01; 3(10):e2023500. PMID: 33125497.
      Citations:    
    71. Puccini A, Poorman K, Salem ME, Soldato D, Seeber A, Goldberg RM, Shields AF, Xiu J, Battaglin F, Berger MD, Tokunaga R, Naseem M, Barzi A, Iqbal S, Zhang W, Soni S, Hwang JJ, Philip PA, Sciallero S, Korn WM, Marshall JL, Lenz HJ. Comprehensive Genomic Profiling of Gastroenteropancreatic Neuroendocrine Neoplasms (GEP-NENs). Clin Cancer Res. 2020 11 15; 26(22):5943-5951. PMID: 32883742.
      Citations:    
    72. Guercio BJ, Zhang S, Ou FS, Venook AP, Niedzwiecki D, Lenz HJ, Innocenti F, Pollak MN, Nixon AB, Mullen BC, O'Neil BH, Shaw JE, Polite BN, Benson AB, Atkins JN, Goldberg RM, Brown JC, O'Reilly EM, Mayer RJ, Blanke CD, Fuchs CS, Meyerhardt JA. IGF-Binding Proteins, Adiponectin, and Survival in Metastatic Colorectal Cancer: Results From CALGB (Alliance)/SWOG 80405. JNCI Cancer Spectr. 2021 02; 5(1). PMID: 33426464.
      Citations:    
    73. Liu Y, Lyu J, Bell Burdett K, Sibley AB, Hatch AJ, Starr MD, Brady JC, Hammond K, Marmorino F, Rossini D, Goldberg RM, Falcone A, Cremolini C, Owzar K, Ivanova A, Moore DT, Lee MS, Sanoff HK, Innocenti F, Nixon AB. Prognostic and Predictive Biomarkers in Patients with Metastatic Colorectal Cancer Receiving Regorafenib. Mol Cancer Ther. 2020 10; 19(10):2146-2154. PMID: 32747417.
      Citations:    
    74. Salem ME, Bodor JN, Puccini A, Xiu J, Goldberg RM, Grothey A, Korn WM, Shields AF, Worrilow WM, Kim ES, Lenz HJ, Marshall JL, Hall MJ. Relationship between MLH1, PMS2, MSH2 and MSH6 gene-specific alterations and tumor mutational burden in 1057 microsatellite instability-high solid tumors. Int J Cancer. 2020 11 15; 147(10):2948-2956. PMID: 32449172.
      Citations:    
    75. Spizzo G, Puccini A, Xiu J, Goldberg RM, Grothey A, Shields AF, Arora SP, Khushman M, Salem ME, Battaglin F, Baca Y, El-Deiry WS, Philip PA, Nassem M, Hall M, Marshall JL, Kocher F, Amann A, Wolf D, Korn WM, Lenz HJ, Seeber A. Molecular profile of BRCA-mutated biliary tract cancers. ESMO Open. 2020 06; 5(3):e000682. PMID: 32576609.
      Citations:    
    76. Zimmer K, Puccini A, Xiu J, Baca Y, Spizzo G, Lenz HJ, Battaglin F, Goldberg RM, Grothey A, Shields AF, Salem ME, Marshall JL, Korn WM, Wolf D, Kocher F, Seeber A. WRN-Mutated Colorectal Cancer Is Characterized by a Distinct Genetic Phenotype. Cancers (Basel). 2020 May 22; 12(5). PMID: 32455893.
      Citations:    
    77. Sinicrope FA, Shi Q, Hermitte F, Zemla TJ, Mlecnik B, Benson AB, Gill S, Goldberg RM, Kahlenberg MS, Nair SG, Shields AF, Smyrk TC, Galon J, Alberts SR. Contribution of Immunoscore and Molecular Features to Survival Prediction in Stage III Colon Cancer. JNCI Cancer Spectr. 2020 Jun; 4(3):pkaa023. PMID: 32455336.
      Citations:    
    78. Guercio BJ, Zhang S, Venook AP, Ou FS, Niedzwiecki D, Lenz HJ, Innocenti F, Mullen BC, O'Neil BH, Shaw JE, Polite BN, Hochster HS, Atkins JN, Goldberg RM, Brown JC, O'Reilly EM, Mayer RJ, Blanke CD, Fuchs CS, Meyerhardt JA. Body Mass Index and Weight Loss in Metastatic Colorectal Cancer in CALGB (Alliance)/SWOG 80405. JNCI Cancer Spectr. 2020 Jun; 4(3):pkaa024. PMID: 33134818.
      Citations:    
    79. Cohen R, Vernerey D, Bellera C, Meurisse A, Henriques J, Paoletti X, Rousseau B, Alberts S, Aparicio T, Boukovinas I, Gill S, Goldberg RM, Grothey A, Hamaguchi T, Iveson T, Kerr R, Labianca R, Lonardi S, Meyerhardt J, Paul J, Punt CJA, Saltz L, Saunders MP, Schmoll HJ, Shah M, Sobrero A, Souglakos I, Taieb J, Takashima A, Wagner AD, Ychou M, Bonnetain F, Gourgou S, Yoshino T, Yothers G, de Gramont A, Shi Q, Andr? T. Guidelines for time-to-event end-point definitions in adjuvant randomised trials for patients with localised colon cancer: Results of the DATECAN initiative. Eur J Cancer. 2020 05; 130:63-71. PMID: 32172199.
      Citations:    
    80. Zaanan A, Shi Q, Taieb J, Alberts SR, Meyers JP, Smyrk TC, Julie C, Zawadi A, Tabernero J, Mini E, Goldberg RM, Folprecht G, Van Laethem JL, Le Malicot K, Sargent DJ, Laurent-Puig P, Sinicrope FA. Clinical Outcomes in Patients With Colon Cancer With Microsatellite Instability of Sporadic or Familial Origin Treated With Adjuvant FOLFOX With or Without Cetuximab: A Pooled Analysis of the PETACC8 and N0147 Trials. JCO Precis Oncol. 2020; 4. PMID: 32923882.
      Citations:    
    81. Salem ME, Battaglin F, Goldberg RM, Puccini A, Shields AF, Arguello D, Korn WM, Marshall JL, Grothey A, Lenz HJ. Molecular Analyses of Left- and Right-Sided Tumors in Adolescents and Young Adults with Colorectal Cancer. Oncologist. 2020 05; 25(5):404-413. PMID: 31848314.
      Citations:    
    82. Penney KL, Banbury BL, Bien S, Harrison TA, Hua X, Phipps AI, Sun W, Song M, Joshi AD, Alberts SR, Allegra CJ, Atkins J, Colangelo LH, George TJ, Goldberg RM, Lucas PC, Nair SG, Shi Q, Sinicrope FA, Wolmark N, Yothers G, Peters U, Newcomb PA, Chan AT. Genetic Variant Associated With Survival of Patients With Stage II-III Colon Cancer. Clin Gastroenterol Hepatol. 2020 11; 18(12):2717-2723.e3. PMID: 31811950.
      Citations:    
    83. Abou-Alfa GK, Shi Q, Knox JJ, Kaubisch A, Niedzwiecki D, Posey J, Tan BR, Kavan P, Goel R, Lammers PE, Bekaii-Saab TS, Tam VC, Rajdev L, Kelley RK, El Dika I, Zemla T, Potaracke RI, Balletti J, El-Khoueiry AB, Harding JJ, Suga JM, Schwartz LH, Goldberg RM, Bertagnolli MM, Meyerhardt J, O'Reilly EM, Venook AP. Assessment of Treatment With Sorafenib Plus Doxorubicin vs Sorafenib Alone in Patients With Advanced Hepatocellular Carcinoma: Phase 3 CALGB 80802 Randomized Clinical Trial. JAMA Oncol. 2019 Nov 01; 5(11):1582-1588. PMID: 31486832.
      Citations:    
    84. Brown JC, Zhang S, Ou FS, Venook AP, Niedzwiecki D, Lenz HJ, Innocenti F, O'Neil BH, Shaw JE, Polite BN, Denlinger CS, Atkins JN, Goldberg RM, Ng K, Mayer RJ, Blanke CD, O'Reilly EM, Fuchs CS, Meyerhardt JA. Diabetes and Clinical Outcome in Patients With Metastatic Colorectal Cancer: CALGB 80405 (Alliance). JNCI Cancer Spectr. 2020 Feb; 4(1):pkz078. PMID: 32259016.
      Citations:    
    85. Travaglini LE, Kreyenbuhl J, Graydon M, Brown CH, Goldberg R, Himelhoch S, Fang LJ, Slade E. Access to Direct-Acting Antiviral Treatment for Hepatitis C Virus Among Veterans With Serious Mental Illness. Psychiatr Serv. 2020 02 01; 71(2):192-195. PMID: 31615365.
      Citations:    
    86. Yuan C, Sato K, Hollis BW, Zhang S, Niedzwiecki D, Ou FS, Chang IW, O'Neil BH, Innocenti F, Lenz HJ, Blanke CD, Goldberg RM, Venook AP, Mayer RJ, Fuchs CS, Meyerhardt JA, Ng K. Plasma 25-Hydroxyvitamin D Levels and Survival in Patients with Advanced or Metastatic Colorectal Cancer: Findings from CALGB/SWOG 80405 (Alliance). Clin Cancer Res. 2019 12 15; 25(24):7497-7505. PMID: 31548349.
      Citations:    
    87. Burzykowski T, Coart E, Saad ED, Shi Q, Sommeijer DW, Bokemeyer C, D?az-Rubio E, Douillard JY, Falcone A, Fuchs CS, Goldberg RM, Hecht JR, Hoff PM, Hurwitz H, Kabbinavar FF, Koopman M, Maughan TS, Punt CJA, Saltz L, Schmoll HJ, Seymour MT, Tebbutt NC, Tournigand C, Van Cutsem E, de Gramont A, Zalcberg JR, Buyse M. Evaluation of Continuous Tumor-Size-Based End Points as Surrogates for Overall Survival in Randomized Clinical Trials in Metastatic Colorectal Cancer. JAMA Netw Open. 2019 Sep 04; 2(9):e1911750. PMID: 31539075.
      Citations:    
    88. Guercio BJ, Zhang S, Ou FS, Venook AP, Niedzwiecki D, Lenz HJ, Innocenti F, O'Neil BH, Shaw JE, Polite BN, Hochster HS, Atkins JN, Goldberg RM, Sato K, Ng K, Van Blarigan E, Mayer RJ, Blanke CD, O'Reilly EM, Fuchs CS, Meyerhardt JA. Associations of Physical Activity With Survival and Progression in Metastatic Colorectal Cancer: Results From Cancer and Leukemia Group B (Alliance)/SWOG 80405. J Clin Oncol. 2019 10 10; 37(29):2620-2631. PMID: 31408415.
      Citations:    
    89. Innocenti F, Ou FS, Qu X, Zemla T, Niedzwiecki D, Tam R, Mahajan S, Goldberg RM, Bertagnolli MM, Blanke CD, Sanoff H, Atkins J, Polite B, Venook AP, Lenz HJ, Kabbarah O. Reply to S. Sorscher. J Clin Oncol. 2019 09 01; 37(25):2291-2293. PMID: 31268798.
      Citations:    
    90. Phalen PL, Muralidharan A, Travaglini L, Bennett M, Stahl N, Brown C, Hack S, Klingaman EA, Goldberg R. Predictors of attendance in health and wellness treatment groups for people with serious mental illness. Psychiatr Rehabil J. 2020 Jun; 43(2):149-155. PMID: 31259581.
      Citations:    
    91. Adjei A, Buckner JC, Cathcart-Rake E, Chen H, Cohen HJ, Dao D, De Luca JE, Feliciano J, Freedman RA, Goldberg RM, Hopkins J, Hubbard J, Jatoi A, Karuturi M, Kemeny M, Kimmick GG, Klepin HD, Krok-Schoen JL, Lafky JM, Le-Rademacher JG, Li D, Lichtman SM, Maggiore R, Mandelblatt J, Morrison VA, Muss HB, Ojelabi MO, Sedrak MS, Subbiah N, Sun V, Tuttle S, VanderWalde N, Wildes T, Wong ML, Woyach J. Arti Hurria, M.D.: A tribute to her shining legacy in the Alliance for Clinical Trials in Oncology. J Geriatr Oncol. 2020 03; 11(2):179-183. PMID: 31201095.
      Citations:    
    92. El-Deiry WS, Goldberg RM, Lenz HJ, Shields AF, Gibney GT, Tan AR, Brown J, Eisenberg B, Heath EI, Phuphanich S, Kim E, Brenner AJ, Marshall JL. The current state of molecular testing in the treatment of patients with solid tumors, 2019. CA Cancer J Clin. 2019 07; 69(4):305-343. PMID: 31116423.
      Citations:    
    93. Yuan C, Renfro L, Ambadwar PB, Ou FS, McLeod HL, Innocenti F, Meyerhardt JA, Wolpin BM, Goldberg RM, Grothey A, Fuchs CS, Ng K. Influence of genetic variation in the vitamin D pathway on plasma 25-hydroxyvitamin D3 levels and survival among patients with metastatic colorectal cancer. Cancer Causes Control. 2019 Jul; 30(7):757-765. PMID: 31104167.
      Citations:    
    94. Lenz HJ, Ou FS, Venook AP, Hochster HS, Niedzwiecki D, Goldberg RM, Mayer RJ, Bertagnolli MM, Blanke CD, Zemla T, Qu X, Wirapati P, Tejpar S, Innocenti F, Kabbarah O. Impact of Consensus Molecular Subtype on Survival in Patients With Metastatic Colorectal Cancer: Results From CALGB/SWOG 80405 (Alliance). J Clin Oncol. 2019 08 01; 37(22):1876-1885. PMID: 31042420.
      Citations:    
    95. Innocenti F, Ou FS, Qu X, Zemla TJ, Niedzwiecki D, Tam R, Mahajan S, Goldberg RM, Bertagnolli MM, Blanke CD, Sanoff H, Atkins J, Polite B, Venook AP, Lenz HJ, Kabbarah O. Mutational Analysis of Patients With Colorectal Cancer in CALGB/SWOG 80405 Identifies New Roles of Microsatellite Instability and Tumor Mutational Burden for Patient Outcome. J Clin Oncol. 2019 05 10; 37(14):1217-1227. PMID: 30865548.
      Citations:    
    96. Tokunaga R, Xiu J, Johnston C, Goldberg RM, Philip PA, Seeber A, Naseem M, Lo JH, Arai H, Battaglin F, Puccini A, Berger MD, Soni S, Zhang W, Hwang JJ, Shields AF, Marshall JL, Baba H, Korn WM, Lenz HJ. Molecular Profiling of Appendiceal Adenocarcinoma and Comparison with Right-sided and Left-sided Colorectal Cancer. Clin Cancer Res. 2019 05 15; 25(10):3096-3103. PMID: 30692096.
      Citations:    
    97. Puccini A, Lenz HJ, Marshall JL, Arguello D, Raghavan D, Korn WM, Weinberg BA, Poorman K, Heeke AL, Philip PA, Shields AF, Goldberg RM, Salem ME. Impact of Patient Age on Molecular Alterations of Left-Sided Colorectal Tumors. Oncologist. 2019 03; 24(3):319-326. PMID: 30018131.
      Citations:    
    98. Sanoff HK, Goldberg RM, Ivanova A, O'Reilly S, Kasbari SS, Kim RD, McDermott R, Moore DT, Zamboni W, Grogan W, Cohn AL, Bekaii-Saab TS, Leonard G, Ryan T, Olowokure OO, Fernando NH, McCaffrey J, El-Rayes BF, Horgan AM, Sherrill GB, Yacoub GH, O'Neil BH. Multicenter, randomized, double-blind phase 2 trial of FOLFIRI with regorafenib or placebo as second-line therapy for metastatic colorectal cancer. Cancer. 2018 08 01; 124(15):3118-3126. PMID: 29905927.
      Citations:    
    99. Salem ME, Puccini A, Xiu J, Raghavan D, Lenz HJ, Korn WM, Shields AF, Philip PA, Marshall JL, Goldberg RM. Comparative Molecular Analyses of Esophageal Squamous Cell Carcinoma, Esophageal Adenocarcinoma, and Gastric Adenocarcinoma. Oncologist. 2018 11; 23(11):1319-1327. PMID: 29866946.
      Citations:    
    100. Sjoquist KM, Renfro LA, Simes RJ, Tebbutt NC, Clarke S, Seymour MT, Adams R, Maughan TS, Saltz L, Goldberg RM, Schmoll HJ, Van Cutsem E, Douillard JY, Hoff PM, Hecht JR, Tournigand C, Punt CJA, Koopman M, Hurwitz H, Heinemann V, Falcone A, Porschen R, Fuchs C, Diaz-Rubio E, Aranda E, Bokemeyer C, Souglakos I, Kabbinavar FF, Chibaudel B, Meyers JP, Sargent DJ, de Gramont A, Zalcberg JR. Personalizing Survival Predictions in Advanced Colorectal Cancer: The ARCAD Nomogram Project. J Natl Cancer Inst. 2018 06 01; 110(6):638-648. PMID: 29267900.
      Citations:    
    101. Hampel H, Pearlman R, Beightol M, Zhao W, Jones D, Frankel WL, Goodfellow PJ, Yilmaz A, Miller K, Bacher J, Jacobson A, Paskett E, Shields PG, Goldberg RM, de la Chapelle A, Shirts BH, Pritchard CC. Assessment of Tumor Sequencing as a Replacement for Lynch Syndrome Screening and Current Molecular Tests for Patients With Colorectal Cancer. JAMA Oncol. 2018 06 01; 4(6):806-813. PMID: 29596542.
      Citations:    
    102. Das S, Ciombor KK, Haraldsdottir S, Goldberg RM. Promising New Agents for Colorectal Cancer. Curr Treat Options Oncol. 2018 05 11; 19(6):29. PMID: 29752549.
      Citations:    
    103. Goldberg RM, Montagut C, Wainberg ZA, Ronga P, Audhuy F, Taieb J, Stintzing S, Siena S, Santini D. Optimising the use of cetuximab in the continuum of care for patients with metastatic colorectal cancer. ESMO Open. 2018; 3(4):e000353. PMID: 29765773.
      Citations:    
    104. Phipps AI, Shi Q, Zemla TJ, Dotan E, Gill S, Goldberg RM, Hardikar S, Jahagirdar B, Limburg PJ, Newcomb PA, Shields A, Sinicrope FA, Sargent DJ, Alberts SR. Physical Activity and Outcomes in Patients with Stage III Colon Cancer: A Correlative Analysis of Phase III Trial NCCTG N0147 (Alliance). Cancer Epidemiol Biomarkers Prev. 2018 06; 27(6):696-703. PMID: 29563133.
      Citations:    
    105. Salem ME, Puccini A, Grothey A, Raghavan D, Goldberg RM, Xiu J, Korn WM, Weinberg BA, Hwang JJ, Shields AF, Marshall JL, Philip PA, Lenz HJ. Landscape of Tumor Mutation Load, Mismatch Repair Deficiency, and PD-L1 Expression in a Large Patient Cohort of Gastrointestinal Cancers. Mol Cancer Res. 2018 05; 16(5):805-812. PMID: 29523759.
      Citations:    
    106. Zaanan A, Shi Q, Taieb J, Alberts SR, Meyers JP, Smyrk TC, Julie C, Zawadi A, Tabernero J, Mini E, Goldberg RM, Folprecht G, Van Laethem JL, Le Malicot K, Sargent DJ, Laurent-Puig P, Sinicrope FA. Role of Deficient DNA Mismatch Repair Status in Patients With Stage III Colon Cancer Treated With FOLFOX Adjuvant Chemotherapy: A Pooled Analysis From 2 Randomized Clinical Trials. JAMA Oncol. 2018 Mar 01; 4(3):379-383. PMID: 28983557.
      Citations:    
    107. Ciombor KK, Goldberg RM. Hypermutated Tumors and Immune Checkpoint Inhibition. Drugs. 2018 Feb; 78(2):155-162. PMID: 29350327.
      Citations:    
    108. Ahn DH, Wu C, Wei L, Williams TM, Wuthrick E, Abdel-Misih S, Harzman A, Husain S, Schmidt C, Goldberg RM, Bekaii-Saab T. The Efficacy of Adjuvant Chemotherapy in Patients With Stage II/III Resected Rectal Cancer Treated With Neoadjuvant Chemoradiation Therapy. Am J Clin Oncol. 2017 Dec; 40(6):531-534. PMID: 25723741.
      Citations:    
    109. Goldberg RM, Wei L, Fernandez S. In Reply. Oncologist. 2018 01; 23(1):136. PMID: 29133518.
      Citations:    
    110. Le DT, Hubbard-Lucey VM, Morse MA, Heery CR, Dwyer A, Marsilje TH, Brodsky AN, Chan E, Deming DA, Diaz LA, Fridman WH, Goldberg RM, Hamilton SR, Housseau F, Jaffee EM, Kang SP, Krishnamurthi SS, Lieu CH, Messersmith W, Sears CL, Segal NH, Yang A, Moss RA, Cha E, O'Donnell-Tormey J, Roach N, Davis AQ, McAbee K, Worrall S, Benson AB. A Blueprint to Advance Colorectal Cancer Immunotherapies. Cancer Immunol Res. 2017 11; 5(11):942-949. PMID: 29038296.
      Citations:    
    111. Fuchs CS, Niedzwiecki D, Mamon HJ, Tepper JE, Ye X, Swanson RS, Enzinger PC, Haller DG, Dragovich T, Alberts SR, Bjarnason GA, Willett CG, Gunderson LL, Goldberg RM, Venook AP, Ilson D, O'Reilly E, Ciombor K, Berg DJ, Meyerhardt J, Mayer RJ. Adjuvant Chemoradiotherapy With Epirubicin, Cisplatin, and Fluorouracil Compared With Adjuvant Chemoradiotherapy With Fluorouracil and Leucovorin After Curative Resection of Gastric Cancer: Results From CALGB 80101 (Alliance). J Clin Oncol. 2017 Nov 10; 35(32):3671-3677. PMID: 28976791.
      Citations:    
    112. Wing MR, Reeser JW, Smith AM, Reeder M, Martin D, Jewell BM, Datta J, Miya J, Monk JP, Mortazavi A, Otterson GA, Goldberg RM, VanDeusen JB, Cole S, Dittmar K, Jaiswal S, Kinzie M, Waikhom S, Freud AG, Zhou XP, Chen W, Bhatt D, Roychowdhury S. Analytic validation and real-time clinical application of an amplicon-based targeted gene panel for advanced cancer. Oncotarget. 2017 Sep 29; 8(44):75822-75833. PMID: 29100271.
      Citations:    
    113. Dotan E, Cohen SJ, Starodub AN, Lieu CH, Messersmith WA, Simpson PS, Guarino MJ, Marshall JL, Goldberg RM, Hecht JR, Wegener WA, Sharkey RM, Govindan SV, Goldenberg DM, Berlin JD. Phase I/II Trial of Labetuzumab Govitecan (Anti-CEACAM5/SN-38 Antibody-Drug Conjugate) in Patients With Refractory or Relapsing Metastatic Colorectal Cancer. J Clin Oncol. 2017 Oct 10; 35(29):3338-3346. PMID: 28817371.
      Citations:    
    114. Venook AP, Niedzwiecki D, Lenz HJ, Innocenti F, Fruth B, Meyerhardt JA, Schrag D, Greene C, O'Neil BH, Atkins JN, Berry S, Polite BN, O'Reilly EM, Goldberg RM, Hochster HS, Schilsky RL, Bertagnolli MM, El-Khoueiry AB, Watson P, Benson AB, Mulkerin DL, Mayer RJ, Blanke C. Effect of First-Line Chemotherapy Combined With Cetuximab or Bevacizumab on Overall Survival in Patients With KRAS Wild-Type Advanced or Metastatic Colorectal Cancer: A Randomized Clinical Trial. JAMA. 2017 06 20; 317(23):2392-2401. PMID: 28632865.
      Citations:    
    115. Goldberg RM, Wei L, Fernandez S. The Evolution of Clinical Trials in Oncology: Defining Who Benefits from New Drugs Using Innovative Study Designs. Oncologist. 2017 09; 22(9):1015-1019. PMID: 28620092.
      Citations:    
    116. Le DT, Durham JN, Smith KN, Wang H, Bartlett BR, Aulakh LK, Lu S, Kemberling H, Wilt C, Luber BS, Wong F, Azad NS, Rucki AA, Laheru D, Donehower R, Zaheer A, Fisher GA, Crocenzi TS, Lee JJ, Greten TF, Duffy AG, Ciombor KK, Eyring AD, Lam BH, Joe A, Kang SP, Holdhoff M, Danilova L, Cope L, Meyer C, Zhou S, Goldberg RM, Armstrong DK, Bever KM, Fader AN, Taube J, Housseau F, Spetzler D, Xiao N, Pardoll DM, Papadopoulos N, Kinzler KW, Eshleman JR, Vogelstein B, Anders RA, Diaz LA. Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. Science. 2017 07 28; 357(6349):409-413. PMID: 28596308.
      Citations:    
    117. Haraldsdottir S, Rafnar T, Frankel WL, Einarsdottir S, Sigurdsson A, Hampel H, Snaebjornsson P, Masson G, Weng D, Arngrimsson R, Kehr B, Yilmaz A, Haraldsson S, Sulem P, Stefansson T, Shields PG, Sigurdsson F, Bekaii-Saab T, Moller PH, Steinarsdottir M, Alexiusdottir K, Hitchins M, Pritchard CC, de la Chapelle A, Jonasson JG, Goldberg RM, Stefansson K. Comprehensive population-wide analysis of Lynch syndrome in Iceland reveals founder mutations in MSH6 and PMS2. Nat Commun. 2017 05 03; 8:14755. PMID: 28466842.
      Citations:    
    118. Chinman M, Daniels K, Smith J, McCarthy S, Medoff D, Peeples A, Goldberg R. Provision of peer specialist services in VA patient aligned care teams: protocol for testing a cluster randomized implementation trial. Implement Sci. 2017 05 02; 12(1):57. PMID: 28464935.
      Citations:    
    119. Renfro LA, Goldberg RM, Grothey A, Sobrero A, Adams R, Seymour MT, Heinemann V, Schmoll HJ, Douillard JY, Hurwitz H, Fuchs CS, Diaz-Rubio E, Porschen R, Tournigand C, Chibaudel B, Hoff PM, Kabbinavar FF, Falcone A, Tebbutt NC, Punt CJA, Hecht JR, Souglakos J, Bokemeyer C, Van Cutsem E, Saltz L, de Gramont A, Sargent DJ. Clinical Calculator for Early Mortality in Metastatic Colorectal Cancer: An Analysis of Patients From 28 Clinical Trials in the Aide et Recherche en Canc?rologie Digestive Database. J Clin Oncol. 2017 Jun 10; 35(17):1929-1937. PMID: 28414610.
      Citations:    
    120. Young AS, Cohen AN, Goldberg R, Hellemann G, Kreyenbuhl J, Niv N, Nowlin-Finch N, Oberman R, Whelan F. Improving Weight in People with Serious Mental Illness: The Effectiveness of Computerized Services with Peer Coaches. J Gen Intern Med. 2017 Apr; 32(Suppl 1):48-55. PMID: 28271427.
      Citations:    
    121. Sinicrope FA, Shi Q, Allegra CJ, Smyrk TC, Thibodeau SN, Goldberg RM, Meyers JP, Pogue-Geile KL, Yothers G, Sargent DJ, Alberts SR. Association of DNA Mismatch Repair and Mutations in BRAF and KRAS With Survival After Recurrence in Stage III Colon Cancers : A Secondary Analysis of 2 Randomized Clinical Trials. JAMA Oncol. 2017 Apr 01; 3(4):472-480. PMID: 28006055.
      Citations:    
    122. Pearlman R, Frankel WL, Swanson B, Zhao W, Yilmaz A, Miller K, Bacher J, Bigley C, Nelsen L, Goodfellow PJ, Goldberg RM, Paskett E, Shields PG, Freudenheim JL, Stanich PP, Lattimer I, Arnold M, Liyanarachchi S, Kalady M, Heald B, Greenwood C, Paquette I, Prues M, Draper DJ, Lindeman C, Kuebler JP, Reynolds K, Brell JM, Shaper AA, Mahesh S, Buie N, Weeman K, Shine K, Haut M, Edwards J, Bastola S, Wickham K, Khanduja KS, Zacks R, Pritchard CC, Shirts BH, Jacobson A, Allen B, de la Chapelle A, Hampel H. Prevalence and Spectrum of Germline Cancer Susceptibility Gene Mutations Among Patients With Early-Onset Colorectal Cancer. JAMA Oncol. 2017 Apr 01; 3(4):464-471. PMID: 27978560.
      Citations:    
    123. Ciombor KK, Goldberg RM. Primary Tumor Sidedness as Prognostic and Predictive Biomarker in Metastatic Colorectal Cancer: Further Validation of a Potentially Practice-Changing Variable. JAMA Oncol. 2017 Feb 01; 3(2):165-166. PMID: 27722749.
      Citations:    
    124. Jansson-Knodell CL, Foster NR, Sargent DJ, Limburg PJ, Thibodeau SN, Smyrk TC, Sinicrope FA, Jahagirdar B, Goldberg RM, Alberts SR. Family history of colorectal cancer and its impact on survival in patients with resected stage III colon cancer: results from NCCTG Trial N0147 (Alliance). J Gastrointest Oncol. 2017 Feb; 8(1):1-11. PMID: 28280603.
      Citations:    
    125. Niedzwiecki D, Frankel WL, Venook AP, Ye X, Friedman PN, Goldberg RM, Mayer RJ, Colacchio TA, Mulligan JM, Davison TS, O'Brien E, Kerr P, Johnston PG, Kennedy RD, Harkin DP, Schilsky RL, Bertagnolli MM, Warren RS, Innocenti F. Reply to L. Casadaban et al. J Clin Oncol. 2017 04 20; 35(12):1373-1374. PMID: 28113023.
      Citations:    
    126. Taieb J, Le Malicot K, Shi Q, Penault-Llorca F, Bouch? O, Tabernero J, Mini E, Goldberg RM, Folprecht G, Luc Van Laethem J, Sargent DJ, Alberts SR, Emile JF, Laurent Puig P, Sinicrope FA. Prognostic Value of BRAF?and?KRAS?Mutations in MSI and MSS Stage III Colon Cancer. J Natl Cancer Inst. 2017 05; 109(5). PMID: 28040692.
      Citations:    
    127. Ciombor KK, Goldberg RM. Highlights in Gastrointestinal (Colorectal) Cancer Treatment: The Primary Tumor Sidedness Debate and Advances in Immunotherapy. JAMA Oncol. 2016 Dec 01; 2(12):1537-1538. PMID: 27684887.
      Citations:    
    128. Singh PP, Shi Q, Foster NR, Grothey A, Nair SG, Chan E, Shields AF, Goldberg RM, Gill S, Kahlenberg MS, Sinicrope FA, Sargent DJ, Alberts SR. Relationship Between Metformin Use and Recurrence and Survival in Patients With Resected Stage III Colon Cancer Receiving Adjuvant Chemotherapy: Results From North Central Cancer Treatment Group N0147 (Alliance). Oncologist. 2016 12; 21(12):1509-1521. PMID: 27881709.
      Citations:    
    129. Goldberg RM. In Memoriam: A Tribute to Daniel J. Sargent, Ph.D. Oncologist. 2016 12; 21(12):1540-1541. PMID: 27956661.
      Citations:    
    130. Niedzwiecki D, Hasson RM, Lenz HJ, Ye C, Redston M, Ogino S, Fuchs CS, Compton CC, Mayer RJ, Goldberg RM, Colacchio TA, Saltz LB, Warren RS, Bertagnolli MM. A Study of Thymidylate Synthase Expression as a Biomarker for Resectable Colon Cancer: Alliance (Cancer and Leukemia Group B) 9581 and 89803. Oncologist. 2017 01; 22(1):107-114. PMID: 27821793.
      Citations:    
    131. Zhu J, Deane NG, Lewis KB, Padmanabhan C, Washington MK, Ciombor KK, Timmers C, Goldberg RM, Beauchamp RD, Chen X. Evaluation of frozen tissue-derived prognostic gene expression signatures in FFPE colorectal cancer samples. Sci Rep. 2016 09 14; 6:33273. PMID: 27623752.
      Citations:    
    132. Niedzwiecki D, Frankel WL, Venook AP, Ye X, Friedman PN, Goldberg RM, Mayer RJ, Colacchio TA, Mulligan JM, Davison TS, O'Brien E, Kerr P, Johnston PG, Kennedy RD, Harkin DP, Schilsky RL, Bertagnolli MM, Warren RS, Innocenti F. Association Between Results of a Gene Expression Signature Assay and Recurrence-Free Interval in Patients With Stage II Colon Cancer in Cancer and Leukemia Group B 9581 (Alliance). J Clin Oncol. 2016 09 01; 34(25):3047-53. PMID: 27432924.
      Citations:    
    133. Enzinger PC, Burtness BA, Niedzwiecki D, Ye X, Douglas K, Ilson DH, Villaflor VM, Cohen SJ, Mayer RJ, Venook A, Benson AB, Goldberg RM. CALGB 80403 (Alliance)/E1206: A Randomized Phase II Study of Three Chemotherapy Regimens Plus Cetuximab in Metastatic Esophageal and Gastroesophageal Junction Cancers. J Clin Oncol. 2016 08 10; 34(23):2736-42. PMID: 27382098.
      Citations:    
    134. Phipps AI, Shi Q, Limburg PJ, Nelson GD, Sargent DJ, Sinicrope FA, Chan E, Gill S, Goldberg RM, Kahlenberg M, Nair S, Shields AF, Newcomb PA, Alberts SR. Alcohol consumption and colon cancer prognosis among participants in north central cancer treatment group phase III trial N0147. Int J Cancer. 2016 09 01; 139(5):986-95. PMID: 27060850.
      Citations:    
    135. Lee AM, Shi Q, Alberts SR, Sargent DJ, Sinicrope FA, Berenberg JL, Grothey A, Polite B, Chan E, Gill S, Kahlenberg MS, Nair SG, Shields AF, Goldberg RM, Diasio RB. Association between DPYD c.1129-5923 C>G/hapB3 and severe toxicity to 5-fluorouracil-based chemotherapy in stage III colon cancer patients: NCCTG N0147 (Alliance). Pharmacogenet Genomics. 2016 Mar; 26(3):133-7. PMID: 26658227.
      Citations:    
    136. Haraldsdottir S, Hampel H, Wu C, Weng DY, Shields PG, Frankel WL, Pan X, de la Chapelle A, Goldberg RM, Bekaii-Saab T. Patients with colorectal cancer associated with Lynch syndrome and MLH1 promoter hypermethylation have similar prognoses. Genet Med. 2016 09; 18(9):863-8. PMID: 26866578.
      Citations:    
    137. Ahn DH, Goldberg RM. Colorectal clinical trials: what is on the horizon? Future Oncol. 2016 Feb; 12(4):525-31. PMID: 26777152.
      Citations:    
    138. Goldberg R. Emerging phase 3 data in relapsed/refractory metastatic colorectal cancer. Clin Adv Hematol Oncol. 2016 Jan; 14(1):30-3. PMID: 27057664.
      Citations:    
    139. Ciombor KK, Goldberg RM. Update on Anti-Angiogenesis Therapy in Colorectal Cancer. Curr Colorectal Cancer Rep. 2015 Dec; 11(6):378-387. PMID: 27551256.
      Citations:    
    140. Goldberg RM. Genomic Profiling in Gastrointestinal Cancer: Are We Ready To Use These Data to Make Treatment Decisions? Oncologist. 2015 Dec; 20(12):1448-56. PMID: 26512044.
      Citations:    
    141. Renfro LA, Loupakis F, Adams RA, Seymour MT, Heinemann V, Schmoll HJ, Douillard JY, Hurwitz H, Fuchs CS, Diaz-Rubio E, Porschen R, Tournigand C, Chibaudel B, Falcone A, Tebbutt NC, Punt CJ, Hecht JR, Bokemeyer C, Van Cutsem E, Goldberg RM, Saltz LB, de Gramont A, Sargent DJ, Lenz HJ. Body Mass Index Is Prognostic in Metastatic Colorectal Cancer: Pooled Analysis of Patients From First-Line Clinical Trials in the ARCAD Database. J Clin Oncol. 2016 Jan 10; 34(2):144-50. PMID: 26503203.
      Citations:    
    142. Mikhail S, Ciombor K, Noonan A, Wu C, Goldberg R, Zhao W, Wei L, Mathey K, Yereb M, Timmers C, Bekaii-Saab T. Upfront molecular testing in patients with advanced gastro-esophageal cancer: Is it time yet? Oncotarget. 2015 Sep 08; 6(26):22206-13. PMID: 26082439.
      Citations:    
    143. Sinicrope FA, Mahoney MR, Yoon HH, Smyrk TC, Thibodeau SN, Goldberg RM, Nelson GD, Sargent DJ, Alberts SR. Analysis of Molecular Markers by Anatomic Tumor Site in Stage III Colon Carcinomas from Adjuvant Chemotherapy Trial NCCTG N0147 (Alliance). Clin Cancer Res. 2015 Dec 01; 21(23):5294-304. PMID: 26187617.
      Citations:    
    144. Tabernero J, Lenz HJ, Siena S, Sobrero A, Falcone A, Ychou M, Humblet Y, Bouch? O, Mineur L, Barone C, Adenis A, Yoshino T, Goldberg RM, Sargent DJ, Wagner A, Laurent D, Teufel M, Jeffers M, Grothey A, Van Cutsem E. Analysis of circulating DNA and protein biomarkers to predict the clinical activity of regorafenib and assess prognosis in patients with metastatic colorectal cancer: a retrospective, exploratory analysis of the CORRECT trial. Lancet Oncol. 2015 Aug; 16(8):937-48. PMID: 26184520.
      Citations:    
    145. Yoon HH, Shi Q, Alberts SR, Goldberg RM, Thibodeau SN, Sargent DJ, Sinicrope FA. Racial Differences in BRAF/KRAS Mutation Rates and Survival in Stage III Colon Cancer Patients. J Natl Cancer Inst. 2015 Oct; 107(10). PMID: 26160882.
      Citations:    
    146. Nordlinger BM, Poston GJ, Goldberg RM. Reply to J.N. Primrose et al and C.-H. K?hne. J Clin Oncol. 2015 Jul 20; 33(21):2408-9. PMID: 26033799.
      Citations:    
    147. Le DT, Uram JN, Wang H, Bartlett BR, Kemberling H, Eyring AD, Skora AD, Luber BS, Azad NS, Laheru D, Biedrzycki B, Donehower RC, Zaheer A, Fisher GA, Crocenzi TS, Lee JJ, Duffy SM, Goldberg RM, de la Chapelle A, Koshiji M, Bhaijee F, Huebner T, Hruban RH, Wood LD, Cuka N, Pardoll DM, Papadopoulos N, Kinzler KW, Zhou S, Cornish TC, Taube JM, Anders RA, Eshleman JR, Vogelstein B, Diaz LA. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015 Jun 25; 372(26):2509-20. PMID: 26028255.
      Citations:    
    148. Bekaii-Saab T, Goldberg R. Therapeutic advances in pancreatic cancer: miles to go before we sleep. J Natl Cancer Inst. 2015 Feb; 107(2). PMID: 25638250.
      Citations:    
    149. Goldberg R, Ringel MD. Ernest L. Mazzaferri, SR., MD 1936-2013. Trans Am Clin Climatol Assoc. 2015; 126:xcix-ci. PMID: 26567406.
      Citations:    
    150. Ciombor KK, Haraldsdottir S, Goldberg RM. How Can Next-Generation Sequencing (Genomics) Help Us in Treating Colorectal Cancer? Curr Colorectal Cancer Rep. 2014 Dec 01; 10(4):372-379. PMID: 25395895.
      Citations:    
    151. Lamont EB, Schilsky RL, He Y, Muss H, Cohen HJ, Hurria A, Meilleur A, Kindler HL, Venook A, Lilenbaum R, Niell H, Goldberg RM, Joffe S. Generalizability of trial results to elderly Medicare patients with advanced solid tumors (Alliance 70802). J Natl Cancer Inst. 2015 Jan; 107(1):336. PMID: 25432408.
      Citations:    
    152. Ng K, Meyerhardt JA, Chan AT, Sato K, Chan JA, Niedzwiecki D, Saltz LB, Mayer RJ, Benson AB, Schaefer PL, Whittom R, Hantel A, Goldberg RM, Venook AP, Ogino S, Giovannucci EL, Fuchs CS. Aspirin and COX-2 inhibitor use in patients with stage III colon cancer. J Natl Cancer Inst. 2015 Jan; 107(1):345. PMID: 25432409.
      Citations:    
    153. Nordlinger B, Poston GJ, Goldberg RM. Should the results of the new EPOC trial change practice in the management of patients with resectable metastatic colorectal cancer confined to the liver? J Clin Oncol. 2015 Jan 20; 33(3):241-3. PMID: 25403221.
      Citations:    
    154. Shi Q, de Gramont A, Grothey A, Zalcberg J, Chibaudel B, Schmoll HJ, Seymour MT, Adams R, Saltz L, Goldberg RM, Punt CJ, Douillard JY, Hoff PM, Hecht JR, Hurwitz H, D?az-Rubio E, Porschen R, Tebbutt NC, Fuchs C, Souglakos J, Falcone A, Tournigand C, Kabbinavar FF, Heinemann V, Van Cutsem E, Bokemeyer C, Buyse M, Sargent DJ. Individual patient data analysis of progression-free survival versus overall survival as a first-line end point for metastatic colorectal cancer in modern randomized trials: findings from the analysis and research in cancers of the digestive system database. J Clin Oncol. 2015 Jan 01; 33(1):22-8. PMID: 25385741.
      Citations:    
    155. Lee AM, Shi Q, Pavey E, Alberts SR, Sargent DJ, Sinicrope FA, Berenberg JL, Goldberg RM, Diasio RB. DPYD variants as predictors of 5-fluorouracil toxicity in adjuvant colon cancer treatment (NCCTG N0147). J Natl Cancer Inst. 2014 Dec; 106(12). PMID: 25381393.
      Citations:    
    156. Blazer M, Wu C, Goldberg RM, Phillips G, Schmidt C, Muscarella P, Wuthrick E, Williams TM, Reardon J, Ellison EC, Bloomston M, Bekaii-Saab T. Neoadjuvant modified (m) FOLFIRINOX for locally advanced unresectable (LAPC) and borderline resectable (BRPC) adenocarcinoma of the pancreas. Ann Surg Oncol. 2015 Apr; 22(4):1153-9. PMID: 25358667.
      Citations:    
    157. Sharma MR, Gray E, Goldberg RM, Sargent DJ, Karrison TG. Resampling the N9741 trial to compare tumor dynamic versus conventional end points in randomized phase II trials. J Clin Oncol. 2015 Jan 01; 33(1):36-41. PMID: 25349295.
      Citations:    
    158. Pavelitz T, Renfro L, Foster NR, Caracol A, Welsch P, Lao VV, Grady WB, Niedzwiecki D, Saltz LB, Bertagnolli MM, Goldberg RM, Rabinovitch PS, Emond M, Monnat RJ, Maizels N. MRE11-deficiency associated with improved long-term disease free survival and overall survival in a subset of stage III colon cancer patients in randomized CALGB 89803 trial. PLoS One. 2014; 9(10):e108483. PMID: 25310185.
      Citations:    
    159. Nichols SD, Albert S, Shirley L, Schmidt C, Abdel-Misih S, El-Dika S, Groce JR, Wu C, Goldberg RM, Bekaii-Saab T, Bloomston M. Outcomes in patients with obstructive jaundice from metastatic colorectal cancer and implications for management. J Gastrointest Surg. 2014 Dec; 18(12):2186-91. PMID: 25300799.
      Citations:    
    160. Ciombor KK, Wu C, Goldberg RM. Recent therapeutic advances in the treatment of colorectal cancer. Annu Rev Med. 2015; 66:83-95. PMID: 25341011.
      Citations:    
    161. Sinicrope FA, Shi Q, Smyrk TC, Thibodeau SN, Dienstmann R, Guinney J, Bot BM, Tejpar S, Delorenzi M, Goldberg RM, Mahoney M, Sargent DJ, Alberts SR. Molecular markers identify subtypes of stage III colon cancer associated with patient outcomes. Gastroenterology. 2015 Jan; 148(1):88-99. PMID: 25305506.
      Citations:    
    162. Lieu CH, Renfro LA, de Gramont A, Meyers JP, Maughan TS, Seymour MT, Saltz L, Goldberg RM, Sargent DJ, Eckhardt SG, Eng C. Association of age with survival in patients with metastatic colorectal cancer: analysis from the ARCAD Clinical Trials Program. J Clin Oncol. 2014 Sep 20; 32(27):2975-84. PMID: 25002720.
      Citations:    
    163. Ciombor KK, Goldberg RM. Current evidence and controversies in the incorporation of biologics for metastatic colorectal cancer. Hepat Oncol. 2014 Jun; 1(3):331-345. PMID: 30190967.
      Citations:    
    164. O'Neil BH, Cainap C, Van Cutsem E, Gorbunova V, Karapetis CS, Berlin J, Goldberg RM, Qin Q, Qian J, Ricker JL, Fischer J, McKee MD, Carlson DM, Kim TW. Randomized phase II open-label study of mFOLFOX6 in combination with linifanib or bevacizumab for metastatic colorectal cancer. Clin Colorectal Cancer. 2014 Sep; 13(3):156-163.e2. PMID: 25066269.
      Citations:    
    165. Gonsalves WI, Mahoney MR, Sargent DJ, Nelson GD, Alberts SR, Sinicrope FA, Goldberg RM, Limburg PJ, Thibodeau SN, Grothey A, Hubbard JM, Chan E, Nair S, Berenberg JL, McWilliams RR. Patient and tumor characteristics and BRAF and KRAS mutations in colon cancer, NCCTG/Alliance N0147. J Natl Cancer Inst. 2014 Jul; 106(7). PMID: 24925349.
      Citations:    
    166. Shiovitz S, Bertagnolli MM, Renfro LA, Nam E, Foster NR, Dzieciatkowski S, Luo Y, Lao VV, Monnat RJ, Emond MJ, Maizels N, Niedzwiecki D, Goldberg RM, Saltz LB, Venook A, Warren RS, Grady WM. CpG island methylator phenotype is associated with response to adjuvant irinotecan-based therapy for stage III colon cancer. Gastroenterology. 2014 Sep; 147(3):637-45. PMID: 24859205.
      Citations:    
    167. McRee AJ, Davies JM, Sanoff HG, Goldberg RM, Bernard S, Dees EC, Keller K, Ivanova A, O'Neil BH. A phase I trial of everolimus in combination with 5-FU/LV, mFOLFOX6 and mFOLFOX6 plus panitumumab in patients with refractory solid tumors. Cancer Chemother Pharmacol. 2014 Jul; 74(1):117-23. PMID: 24819684.
      Citations:    
    168. Sanoff HK, Renfro LA, Poonnen P, Ambadwar P, Sargent DJ, Goldberg RM, McLeod H. Germline variation in colorectal risk Loci does not influence treatment effect or survival in metastatic colorectal cancer. PLoS One. 2014; 9(4):e94727. PMID: 24727911.
      Citations:    
    169. Yoon HH, Tougeron D, Shi Q, Alberts SR, Mahoney MR, Nelson GD, Nair SG, Thibodeau SN, Goldberg RM, Sargent DJ, Sinicrope FA. KRAS codon 12 and 13 mutations in relation to disease-free survival in BRAF-wild-type stage III colon cancers from an adjuvant chemotherapy trial (N0147 alliance). Clin Cancer Res. 2014 Jun 01; 20(11):3033-43. PMID: 24687927.
      Citations:    
    170. Albrecht JS, Gruber-Baldini AL, Hirshon JM, Brown CH, Goldberg R, Rosenberg JH, Comer AC, Furuno JP. Depressive symptoms and hospital readmission in older adults. J Am Geriatr Soc. 2014 Mar; 62(3):495-9. PMID: 24512099.
      Citations:    
    171. Haraldsdottir S, Hampel H, Wei L, Wu C, Frankel W, Bekaii-Saab T, de la Chapelle A, Goldberg RM. Prostate cancer incidence in males with Lynch syndrome. Genet Med. 2014 Jul; 16(7):553-7. PMID: 24434690.
      Citations:    
    172. Huang J, Nair SG, Mahoney MR, Nelson GD, Shields AF, Chan E, Goldberg RM, Gill S, Kahlenberg MS, Quesenberry JT, Thibodeau SN, Smyrk TC, Grothey A, Sinicrope FA, Webb TA, Farr GH, Pockaj BA, Berenberg JL, Mooney M, Sargent DJ, Alberts SR. Comparison of FOLFIRI with or without cetuximab in patients with resected stage III colon cancer; NCCTG (Alliance) intergroup trial N0147. Clin Colorectal Cancer. 2014 Jun; 13(2):100-9. PMID: 24512953.
      Citations:    
    173. Ogino S, Liao X, Imamura Y, Yamauchi M, McCleary NJ, Ng K, Niedzwiecki D, Saltz LB, Mayer RJ, Whittom R, Hantel A, Benson AB, Mowat RB, Spiegelman D, Goldberg RM, Bertagnolli MM, Meyerhardt JA, Fuchs CS. Predictive and prognostic analysis of PIK3CA mutation in stage III colon cancer intergroup trial. J Natl Cancer Inst. 2013 Dec 04; 105(23):1789-98. PMID: 24231454.
      Citations:    
    174. Goetz MP, McKean HA, Reid JM, Mandrekar SJ, Tan AD, Kuffel MA, Safgren SL, McGovern RM, Goldberg RM, Grothey AA, McWilliams R, Erlichman C, Ames MM. UGT1A1 genotype-guided phase I study of irinotecan, oxaliplatin, and capecitabine. Invest New Drugs. 2013 Dec; 31(6):1559-67. PMID: 24114122.
      Citations:    
    175. Nixon AB, Pang H, Starr MD, Friedman PN, Bertagnolli MM, Kindler HL, Goldberg RM, Venook AP, Hurwitz HI. Prognostic and predictive blood-based biomarkers in patients with advanced pancreatic cancer: results from CALGB80303 (Alliance). Clin Cancer Res. 2013 Dec 15; 19(24):6957-66. PMID: 24097873.
      Citations:    
    176. Garrett CR, Bekaii-Saab TS, Ryan T, Fisher GA, Clive S, Kavan P, Shacham-Shmueli E, Buchbinder A, Goldberg RM. Randomized phase 2 study of pegylated SN-38 (EZN-2208) or irinotecan plus cetuximab in patients with advanced colorectal cancer. Cancer. 2013 Dec 15; 119(24):4223-30. PMID: 24105075.
      Citations:    
    177. Sinicrope FA, Mahoney MR, Smyrk TC, Thibodeau SN, Warren RS, Bertagnolli MM, Nelson GD, Goldberg RM, Sargent DJ, Alberts SR. Prognostic impact of deficient DNA mismatch repair in patients with stage III colon cancer from a randomized trial of FOLFOX-based adjuvant chemotherapy. J Clin Oncol. 2013 Oct 10; 31(29):3664-72. PMID: 24019539.
      Citations:    
    178. Warren RS, Atreya CE, Niedzwiecki D, Weinberg VK, Donner DB, Mayer RJ, Goldberg RM, Compton CC, Zuraek MB, Ye C, Saltz LB, Bertagnolli MM. Association of TP53 mutational status and gender with survival after adjuvant treatment for stage III colon cancer: results of CALGB 89803. Clin Cancer Res. 2013 Oct 15; 19(20):5777-87. PMID: 23983256.
      Citations:    
    179. Sanoff HK, Goldberg RM. How we treat metastatic colon cancer in older adults. J Geriatr Oncol. 2013 Oct; 4(4):295-301. PMID: 24472471.
      Citations:    
    180. Haraldsdottir S, Wu C, Bloomston M, Goldberg RM. What is the optimal neo-adjuvant treatment for liver metastasis? Ther Adv Med Oncol. 2013 Jul; 5(4):221-34. PMID: 23858331.
      Citations:    
    181. Raftery L, Tepper JE, Goldberg RM, Blackstock AW, Aklilu M, Bernard SA, Ivanova A, Davies JM, O'Neil BH. A two-cohort phase I study of weekly oxaliplatin and gemcitabine, then oxaliplatin, gemcitabine, and erlotinib during radiotherapy for unresectable pancreatic carcinoma. Am J Clin Oncol. 2013 Jun; 36(3):250-3. PMID: 22547007.
      Citations:    
    182. Venook AP, Niedzwiecki D, Lopatin M, Ye X, Lee M, Friedman PN, Frankel W, Clark-Langone K, Millward C, Shak S, Goldberg RM, Mahmoud NN, Warren RS, Schilsky RL, Bertagnolli MM. Biologic determinants of tumor recurrence in stage II colon cancer: validation study of the 12-gene recurrence score in cancer and leukemia group B (CALGB) 9581. J Clin Oncol. 2013 May 10; 31(14):1775-81. PMID: 23530100.
      Citations:    
    183. Van Loon K, Wigler D, Niedzwiecki D, Venook AP, Fuchs C, Blanke C, Saltz L, Goldberg RM, Meyerhardt JA. Comparison of dietary and lifestyle habits among stage III and metastatic colorectal cancer patients: findings from CALGB 89803 and CALGB 80405. Clin Colorectal Cancer. 2013 Jun; 12(2):95-102. PMID: 23317558.
      Citations:    
    184. Sinicrope FA, Foster NR, Yothers G, Benson A, Seitz JF, Labianca R, Goldberg RM, Degramont A, O'Connell MJ, Sargent DJ. Body mass index at diagnosis and survival among colon cancer patients enrolled in clinical trials of adjuvant chemotherapy. Cancer. 2013 Apr 15; 119(8):1528-36. PMID: 23310947.
      Citations:    
    185. Wu C, Goldberg RM. Colorectal cancer in 2012: Revisiting landmark trials and identifying new therapies. Nat Rev Clin Oncol. 2013 Feb; 10(2):71-2. PMID: 23296108.
      Citations:    
    186. Wu C, Goldberg RM. Managing choices for older patients with colon cancer: adjuvant therapy. Am Soc Clin Oncol Educ Book. 2013. PMID: 23714498.
      Citations:    
    187. Bekaii-Saab T, Goldberg RM. FOLFIRINOX in locally advanced pancreas adenocarcinoma: back to the future? Oncologist. 2013; 18(5):487-9. PMID: 23704222.
      Citations:    
    188. Grothey A, Van Cutsem E, Sobrero A, Siena S, Falcone A, Ychou M, Humblet Y, Bouch? O, Mineur L, Barone C, Adenis A, Tabernero J, Yoshino T, Lenz HJ, Goldberg RM, Sargent DJ, Cihon F, Cupit L, Wagner A, Laurent D. Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet. 2013 Jan 26; 381(9863):303-12. PMID: 23177514.
      Citations:    
    189. Sugihara K, Ohtsu A, Shimada Y, Mizunuma N, Gomi K, Lee PH, Gramont A, Rothenberg ML, Andr? T, Brienza S, Goldberg RM. Analysis of neurosensory adverse events induced by FOLFOX4 treatment in colorectal cancer patients: a comparison between two Asian studies and four Western studies. Cancer Med. 2012 Oct; 1(2):198-206. PMID: 23342269.
      Citations:    
    190. Carpenter WR, Meyer AM, Wu Y, Qaqish B, Sanoff HK, Goldberg RM, Weiner BJ. Translating research into practice: the role of provider-based research networks in the diffusion of an evidence-based colon cancer treatment innovation. Med Care. 2012 Aug; 50(8):737-48. PMID: 22437624.
      Citations:    
    191. Sanoff HK, Carpenter WR, St?rmer T, Goldberg RM, Martin CF, Fine JP, McCleary NJ, Meyerhardt JA, Niland J, Kahn KL, Schymura MJ, Schrag D. Effect of adjuvant chemotherapy on survival of patients with stage III colon cancer diagnosed after age 75 years. J Clin Oncol. 2012 Jul 20; 30(21):2624-34. PMID: 22665536.
      Citations:    
    192. Albrecht JS, Hirshon JM, Goldberg R, Langenberg P, Day HR, Morgan DJ, Comer AC, Harris AD, Furuno JP. Serious mental illness and acute hospital readmission in diabetic patients. Am J Med Qual. 2012 Nov-Dec; 27(6):503-8. PMID: 22539798.
      Citations:    
    193. Alberts SR, Sargent DJ, Nair S, Mahoney MR, Mooney M, Thibodeau SN, Smyrk TC, Sinicrope FA, Chan E, Gill S, Kahlenberg MS, Shields AF, Quesenberry JT, Webb TA, Farr GH, Pockaj BA, Grothey A, Goldberg RM. Effect of oxaliplatin, fluorouracil, and leucovorin with or without cetuximab on survival among patients with resected stage III colon cancer: a randomized trial. JAMA. 2012 Apr 04; 307(13):1383-93. PMID: 22474202.
      Citations:    
    194. Sargent DJ, Buyse M, Matheson A, Goldberg RM, de Gramont A. The ARCAD clinical trials program: an update and invitation. Oncologist. 2012; 17(2):188-91. PMID: 22302228.
      Citations:    
    195. Sanoff HK, Carpenter WR, Freburger J, Li L, Chen K, Zullig LL, Goldberg RM, Schymura MJ, Schrag D. Comparison of adverse events during 5-fluorouracil versus 5-fluorouracil/oxaliplatin adjuvant chemotherapy for stage III colon cancer: a population-based analysis. Cancer. 2012 Sep 01; 118(17):4309-20. PMID: 22294436.
      Citations:    
    196. Vijayaraghavan A, Efrusy MB, G?ke B, Kirchner T, Santas CC, Goldberg RM. Cost-effectiveness of KRAS testing in metastatic colorectal cancer patients in the United States and Germany. Int J Cancer. 2012 Jul 15; 131(2):438-45. PMID: 21898389.
      Citations:    
    197. Franko J, Shi Q, Goldman CD, Pockaj BA, Nelson GD, Goldberg RM, Pitot HC, Grothey A, Alberts SR, Sargent DJ. Treatment of colorectal peritoneal carcinomatosis with systemic chemotherapy: a pooled analysis of north central cancer treatment group phase III trials N9741 and N9841. J Clin Oncol. 2012 Jan 20; 30(3):263-7. PMID: 22162570.
      Citations:    
    198. Ogino S, Shima K, Meyerhardt JA, McCleary NJ, Ng K, Hollis D, Saltz LB, Mayer RJ, Schaefer P, Whittom R, Hantel A, Benson AB, Spiegelman D, Goldberg RM, Bertagnolli MM, Fuchs CS. Predictive and prognostic roles of BRAF mutation in stage III colon cancer: results from intergroup trial CALGB 89803. Clin Cancer Res. 2012 Feb 01; 18(3):890-900. PMID: 22147942.
      Citations:    
    199. Innocenti F, Owzar K, Cox NL, Evans P, Kubo M, Zembutsu H, Jiang C, Hollis D, Mushiroda T, Li L, Friedman P, Wang L, Glubb D, Hurwitz H, Giacomini KM, McLeod HL, Goldberg RM, Schilsky RL, Kindler HL, Nakamura Y, Ratain MJ. A genome-wide association study of overall survival in pancreatic cancer patients treated with gemcitabine in CALGB 80303. Clin Cancer Res. 2012 Jan 15; 18(2):577-84. PMID: 22142827.
      Citations:    
    200. Sugihara K, Ohtsu A, Shimada Y, Mizunuma N, Lee PH, de Gramont A, Goldberg RM, Rothenberg ML, Andr? T, Brienza S, Gomi K. Safety analysis of FOLFOX4 treatment in colorectal cancer patients: a comparison between two Asian studies and four Western studies. Clin Colorectal Cancer. 2012 Jun; 11(2):127-37. PMID: 22099928.
      Citations:    
    201. Yothers G, Sargent DJ, Wolmark N, Goldberg RM, O'Connell MJ, Benedetti JK, Saltz LB, Dignam JJ, Blackstock AW. Outcomes among black patients with stage II and III colon cancer receiving chemotherapy: an analysis of ACCENT adjuvant trials. J Natl Cancer Inst. 2011 Oct 19; 103(20):1498-506. PMID: 21997132.
      Citations:    
    202. Chibaudel B, Bonnetain F, Shi Q, Buyse M, Tournigand C, Sargent DJ, Allegra CJ, Goldberg RM, de Gramont A. Alternative end points to evaluate a therapeutic strategy in advanced colorectal cancer: evaluation of progression-free survival, duration of disease control, and time to failure of strategy--an Aide et Recherche en Cancerologie Digestive Group Study. J Clin Oncol. 2011 Nov 01; 29(31):4199-204. PMID: 21969501.
      Citations:    
    203. An MW, Mandrekar SJ, Branda ME, Hillman SL, Adjei AA, Pitot HC, Goldberg RM, Sargent DJ. Comparison of continuous versus categorical tumor measurement-based metrics to predict overall survival in cancer treatment trials. Clin Cancer Res. 2011 Oct 15; 17(20):6592-9. PMID: 21880789.
      Citations:    
    204. Ng K, Ogino S, Meyerhardt JA, Chan JA, Chan AT, Niedzwiecki D, Hollis D, Saltz LB, Mayer RJ, Benson AB, Schaefer PL, Whittom R, Hantel A, Goldberg RM, Bertagnolli MM, Venook AP, Fuchs CS. Relationship between statin use and colon cancer recurrence and survival: results from CALGB 89803. J Natl Cancer Inst. 2011 Oct 19; 103(20):1540-51. PMID: 21849660.
      Citations:    
    205. Lucas AS, O'Neil BH, Goldberg RM. A decade of advances in cytotoxic chemotherapy for metastatic colorectal cancer. Clin Colorectal Cancer. 2011 Dec; 10(4):238-44. PMID: 21820973.
      Citations:    
    206. Davies JM, Goldberg RM. Treatment of metastatic colorectal cancer. Semin Oncol. 2011 Aug; 38(4):552-60. PMID: 21810514.
      Citations:    
    207. Bertagnolli MM, Redston M, Compton CC, Niedzwiecki D, Mayer RJ, Goldberg RM, Colacchio TA, Saltz LB, Warren RS. Microsatellite instability and loss of heterozygosity at chromosomal location 18q: prospective evaluation of biomarkers for stages II and III colon cancer--a study of CALGB 9581 and 89803. J Clin Oncol. 2011 Aug 10; 29(23):3153-62. PMID: 21747089.
      Citations:    
    208. Niedzwiecki D, Bertagnolli MM, Warren RS, Compton CC, Kemeny NE, Benson AB, Eckhardt SG, Alberts S, Porjosh GN, Kerr DJ, Fields A, Rougier P, Pipas JM, Schwartz JH, Atkins J, O'Rourke M, Perry MC, Goldberg RM, Mayer RJ, Colacchio TA. Documenting the natural history of patients with resected stage II adenocarcinoma of the colon after random assignment to adjuvant treatment with edrecolomab or observation: results from CALGB 9581. J Clin Oncol. 2011 Aug 10; 29(23):3146-52. PMID: 21747085.
      Citations:    
    209. Blanke CD, Goldberg RM, Grothey A, Mooney M, Roach N, Saltz LB, Welch JJ, Wood WA, Meropol NJ. KRAS and colorectal cancer: ethical and pragmatic issues in effecting real-time change in oncology clinical trials and practice. Oncologist. 2011; 16(8):1061-8. PMID: 21737577.
      Citations:    
    210. Roberts AS, Campa MJ, Gottlin EB, Jiang C, Owzar K, Kindler HL, Venook AP, Goldberg RM, O'Reilly EM, Patz EF. Identification of potential prognostic biomarkers in patients with untreated, advanced pancreatic cancer from a phase 3 trial (Cancer and Leukemia Group B 80303). Cancer. 2012 Jan 15; 118(2):571-8. PMID: 21713765.
      Citations:    
    211. Blanke CD, Bot BM, Thomas DM, Bleyer A, Kohne CH, Seymour MT, de Gramont A, Goldberg RM, Sargent DJ. Impact of young age on treatment efficacy and safety in advanced colorectal cancer: a pooled analysis of patients from nine first-line phase III chemotherapy trials. J Clin Oncol. 2011 Jul 10; 29(20):2781-6. PMID: 21646604.
      Citations:    
    212. Heun JM, Grothey A, Branda ME, Goldberg RM, Sargent DJ. Tumor status at 12 weeks predicts survival in advanced colorectal cancer: findings from NCCTG N9741. Oncologist. 2011; 16(6):859-67. PMID: 21632455.
      Citations:    
    213. McRee AJ, Goldberg RM. Optimal management of metastatic colorectal cancer: current status. Drugs. 2011 May 07; 71(7):869-84. PMID: 21568364.
      Citations:    
    214. Sanoff HK, Bernard S, Goldberg RM, Morse MA, Garcia R, Woods L, Moore DT, O'Neil BH. Phase II Study of Capecitabine, Oxaliplatin, and Cetuximab for Advanced Hepatocellular Carcinoma. Gastrointest Cancer Res. 2011 May; 4(3):78-83. PMID: 22043322.
      Citations:    
    215. Dickerson F, Wohlheiter K, Medoff D, Fang L, Kreyenbuhl J, Goldberg R, Brown C, Dixon L. Predictors of quality of life in type 2 diabetes patients with schizophrenia, major mood disorder, and without mental illness. Qual Life Res. 2011 Nov; 20(9):1419-25. PMID: 21424900.
      Citations:    
    216. Ng K, Sargent DJ, Goldberg RM, Meyerhardt JA, Green EM, Pitot HC, Hollis BW, Pollak MN, Fuchs CS. Vitamin D status in patients with stage IV colorectal cancer: findings from Intergroup trial N9741. J Clin Oncol. 2011 Apr 20; 29(12):1599-606. PMID: 21422438.
      Citations:    
    217. McRee AJ, Cowherd S, Wang AZ, Goldberg RM. Chemoradiation therapy in the management of gastrointestinal malignancies. Future Oncol. 2011 Mar; 7(3):409-26. PMID: 21417904.
      Citations:    
    218. Goldberg RM, Ryan DP. Scan? Cure? Sure! Oncologist. 2011; 16(2):254-6. PMID: 21349952.
      Citations:    
    219. Mamon HJ, Niedzwiecki D, Hollis D, Tan BR, Mayer RJ, Tepper JE, Goldberg RM, Blackstock AW, Fuchs CS. A phase 2 trial of gemcitabine, 5-fluorouracil, and radiation therapy in locally advanced nonmetastatic pancreatic adenocarcinoma : cancer and Leukemia Group B (CALGB) 80003. Cancer. 2011 Jun 15; 117(12):2620-8. PMID: 21656739.
      Citations:    
    220. Davies JM, Goldberg RM. Optimum chemotherapy regimens for neoadjuvant therapy of hepatic colorectal metastases. J Surg Oncol. 2010 Dec 15; 102(8):946-54. PMID: 21165997.
      Citations:    
    221. O'Reilly EM, Niedzwiecki D, Hall M, Hollis D, Bekaii-Saab T, Pluard T, Douglas K, Abou-Alfa GK, Kindler HL, Schilsky RL, Goldberg RM. A Cancer and Leukemia Group B phase II study of sunitinib malate in patients with previously treated metastatic pancreatic adenocarcinoma (CALGB 80603). Oncologist. 2010; 15(12):1310-9. PMID: 21148613.
      Citations:    
    222. Allegra CJ, Yothers G, O'Connell MJ, Sharif S, Petrelli NJ, Colangelo LH, Atkins JN, Seay TE, Fehrenbacher L, Goldberg RM, O'Reilly S, Chu L, Azar CA, Lopa S, Wolmark N. Phase III trial assessing bevacizumab in stages II and III carcinoma of the colon: results of NSABP protocol C-08. J Clin Oncol. 2011 Jan 01; 29(1):11-6. PMID: 20940184.
      Citations:    
    223. Goldberg RM, Bertagnolli MM. VICTOR spoiled? J Clin Oncol. 2010 Oct 20; 28(30):4546-8. PMID: 20837951.
      Citations:    
    224. Ng K, Meyerhardt JA, Chan JA, Niedzwiecki D, Hollis DR, Saltz LB, Mayer RJ, Benson AB, Schaefer PL, Whittom R, Hantel A, Goldberg RM, Fuchs CS. Multivitamin use is not associated with cancer recurrence or survival in patients with stage III colon cancer: findings from CALGB 89803. J Clin Oncol. 2010 Oct 01; 28(28):4354-63. PMID: 20805450.
      Citations:    
    225. O'Neil BH, Funkhouser WK, Calvo BF, Meyers MO, Kim HJ, Goldberg RM, Bernard SA, Caskey L, Deal AM, Wright F, Baldwin AS, Tepper JE. Nuclear factor ?-light chain-enhancer of activated B cells is activated by radiotherapy and is prognostic for overall survival in patients with rectal cancer treated with preoperative fluorouracil-based chemoradiotheraphy. Int J Radiat Oncol Biol Phys. 2011 Jul 01; 80(3):705-11. PMID: 20630669.
      Citations:    
    226. Kindler HL, Niedzwiecki D, Hollis D, Sutherland S, Schrag D, Hurwitz H, Innocenti F, Mulcahy MF, O'Reilly E, Wozniak TF, Picus J, Bhargava P, Mayer RJ, Schilsky RL, Goldberg RM. Gemcitabine plus bevacizumab compared with gemcitabine plus placebo in patients with advanced pancreatic cancer: phase III trial of the Cancer and Leukemia Group B (CALGB 80303). J Clin Oncol. 2010 Aug 01; 28(22):3617-22. PMID: 20606091.
      Citations:    
    227. McLeod HL, Sargent DJ, Marsh S, Green EM, King CR, Fuchs CS, Ramanathan RK, Williamson SK, Findlay BP, Thibodeau SN, Grothey A, Morton RF, Goldberg RM. Pharmacogenetic predictors of adverse events and response to chemotherapy in metastatic colorectal cancer: results from North American Gastrointestinal Intergroup Trial N9741. J Clin Oncol. 2010 Jul 10; 28(20):3227-33. PMID: 20530282.
      Citations:    
    228. Novotny PJ, Smith DJ, Guse L, Rummans TA, Hartmann L, Alberts S, Goldberg R, Gregory D, Johnson M, Sloan JA. A pilot study assessing social support among cancer patients enrolled on clinical trials: a comparison of younger versus older adults. Cancer Manag Res. 2010 May 27; 2:133-42. PMID: 21188104.
      Citations:    
    229. Goldberg RM. Strategic options on behalf of patients with metastatic colorectal cancer: mass tumor murder versus serial tumor killing. Onkologie. 2010; 33(6):291-2. PMID: 20523091.
      Citations:    
    230. Raftery L, Goldberg RM. Optimal delivery of cytotoxic chemotherapy for colon cancer. Cancer J. 2010 May-Jun; 16(3):214-9. PMID: 20526099.
      Citations:    
    231. Sanoff HK, Goldberg RM, Pignone MP. Assessing the quality of initial consultations regarding adjuvant colon cancer therapy. Clin Colorectal Cancer. 2010 Apr; 9(2):113-8. PMID: 20378506.
      Citations:    
    232. O'Neil BH, Raftery L, Calvo BF, Chakravarthy AB, Ivanova A, Myers MO, Kim HJ, Chan E, Wise PE, Caskey LS, Bernard SA, Sanoff HK, Goldberg RM, Tepper JE. A phase I study of bortezomib in combination with standard 5-fluorouracil and external-beam radiation therapy for the treatment of locally advanced or metastatic rectal cancer. Clin Colorectal Cancer. 2010 Apr; 9(2):119-25. PMID: 20378507.
      Citations:    
    233. Tang H, Foster NR, Grothey A, Ansell SM, Goldberg RM, Sargent DJ. Comparison of error rates in single-arm versus randomized phase II cancer clinical trials. J Clin Oncol. 2010 Apr 10; 28(11):1936-41. PMID: 20212253.
      Citations:    
    234. McCabe MS, Wood WA, Goldberg RM. When the family requests withholding the diagnosis: who owns the truth? J Oncol Pract. 2010 Mar; 6(2):94-6. PMID: 20592784.
      Citations:    
    235. McCleary NJ, Niedzwiecki D, Hollis D, Saltz LB, Schaefer P, Whittom R, Hantel A, Benson A, Goldberg R, Meyerhardt JA. Impact of smoking on patients with stage III colon cancer: results from Cancer and Leukemia Group B 89803. Cancer. 2010 Feb 15; 116(4):957-66. PMID: 20052723.
      Citations:    
    236. Goldberg RM, Sargent DJ, McLeod H. Leveraging learning from a phase III colorectal cancer clinical trial: outcomes, methodology, meta-analysis and pharmacogenetics. Trans Am Clin Climatol Assoc. 2010; 121:21-32; discussion 32-3. PMID: 20697547.
      Citations:    
    237. Rakhra-Burris TK, Auman JT, Deverka P, Dressler LG, Evans JP, Goldberg RM, Havener TM, Hoskins JM, Jonas DE, Long KM, Motsinger-Reif AA, Irvin WJ, Richards KL, Roederer MW, Valgus JM, Riper Mv, Vernon JA, Zamboni WC, Wagner MJ, Walko CM, Weck KE, Wiltshire T, McLeod HL. Institutional profile. UNC Institute for Pharmacogenomics and Individualized Therapy: interdisciplinary research for individual care. Pharmacogenomics. 2010 Jan; 11(1):13-21. PMID: 20017668.
      Citations:    
    238. de Gramont A, Hubbard J, Shi Q, O'Connell MJ, Buyse M, Benedetti J, Bot B, O'Callaghan C, Yothers G, Goldberg RM, Blanke CD, Benson A, Deng Q, Alberts SR, Andre T, Wolmark N, Grothey A, Sargent D. Association between disease-free survival and overall survival when survival is prolonged after recurrence in patients receiving cytotoxic adjuvant therapy for colon cancer: simulations based on the 20,800 patient ACCENT data set. J Clin Oncol. 2010 Jan 20; 28(3):460-5. PMID: 20008641.
      Citations:    
    239. Ogino S, Meyerhardt JA, Irahara N, Niedzwiecki D, Hollis D, Saltz LB, Mayer RJ, Schaefer P, Whittom R, Hantel A, Benson AB, Goldberg RM, Bertagnolli MM, Fuchs CS. KRAS mutation in stage III colon cancer and clinical outcome following intergroup trial CALGB 89803. Clin Cancer Res. 2009 Dec 01; 15(23):7322-9. PMID: 19934290.
      Citations:    
    240. Goldberg R, Thomas H, Penner L. Issues of concern to emergency physicians in pre-retirement years: a survey. J Emerg Med. 2011 Jun; 40(6):706-13. PMID: 19926431.
      Citations:    
    241. Kulke MH, Tempero MA, Niedzwiecki D, Hollis DR, Kindler HL, Cusnir M, Enzinger PC, Gorsch SM, Goldberg RM, Mayer RJ. Randomized phase II study of gemcitabine administered at a fixed dose rate or in combination with cisplatin, docetaxel, or irinotecan in patients with metastatic pancreatic cancer: CALGB 89904. J Clin Oncol. 2009 Nov 20; 27(33):5506-12. PMID: 19858396.
      Citations:    
    242. Goldberg RM, Sargent DJ, Morton RF, Green E, Sanoff HK, McLeod H, Buckner J. NCCTG Study N9741: leveraging learning from an NCI Cooperative Group phase III trial. Oncologist. 2009 Oct; 14(10):970-8. PMID: 19828593.
      Citations:    
    243. Dixon LB, Medoff D, Goldberg R, Lucksted A, Kreyenbuhl J, DiClemente C, Potts W, Leith J, Brown C, Adams C, Afful J. Is implementation of the 5 A's of smoking cessation at community mental health centers effective for reduction of smoking by patients with serious mental illness? Am J Addict. 2009 Sep-Oct; 18(5):386-92. PMID: 19874158.
      Citations:    
    244. Goldberg RM, O'Neil BH. Colorectal cancer: Irinotecan therapy-following a trail of breadcrumbs? Nat Rev Gastroenterol Hepatol. 2009 Sep; 6(9):507-9. PMID: 19713983.
      Citations:    
    245. Goldberg RM, Meropol NJ, Tabernero J. Accomplishments in 2008 in the treatment of advanced metastatic colorectal cancer. Gastrointest Cancer Res. 2009 Sep; 3(5 Supplement 2):S23-7. PMID: 20011561.
      Citations:    
    246. Sanoff HK, Sargent DJ, Green EM, McLeod HL, Goldberg RM. Racial differences in advanced colorectal cancer outcomes and pharmacogenetics: a subgroup analysis of a large randomized clinical trial. J Clin Oncol. 2009 Sep 01; 27(25):4109-15. PMID: 19636001.
      Citations:    
    247. Gill S, Goldberg RM. Cetuximab, chemotherapy and KRAS status in mCRC. Nat Rev Clin Oncol. 2009 Jul; 6(7):379-80. PMID: 19561631.
      Citations:    
    248. Wong YN, Meropol NJ, Speier W, Sargent D, Goldberg RM, Beck JR. Cost implications of new treatments for advanced colorectal cancer. Cancer. 2009 May 15; 115(10):2081-91. PMID: 19309745.
      Citations:    
    249. Allegra CJ, Yothers G, O'Connell MJ, Sharif S, Colangelo LH, Lopa SH, Petrelli NJ, Goldberg RM, Atkins JN, Seay TE, Fehrenbacher L, O'Reilly S, Chu L, Azar CA, Wolmark N. Initial safety report of NSABP C-08: A randomized phase III study of modified FOLFOX6 with or without bevacizumab for the adjuvant treatment of patients with stage II or III colon cancer. J Clin Oncol. 2009 Jul 10; 27(20):3385-90. PMID: 19414665.
      Citations:    
    250. Hillman SL, An MW, O'Connell MJ, Goldberg RM, Schaefer P, Buckner JC, Sargent DJ. Evaluation of the optimal number of lesions needed for tumor evaluation using the response evaluation criteria in solid tumors: a north central cancer treatment group investigation. J Clin Oncol. 2009 Jul 01; 27(19):3205-10. PMID: 19414682.
      Citations:    
    251. Kim GP, Sargent DJ, Mahoney MR, Rowland KM, Philip PA, Mitchell E, Mathews AP, Fitch TR, Goldberg RM, Alberts SR, Pitot HC. Phase III noninferiority trial comparing irinotecan with oxaliplatin, fluorouracil, and leucovorin in patients with advanced colorectal carcinoma previously treated with fluorouracil: N9841. J Clin Oncol. 2009 Jun 10; 27(17):2848-54. PMID: 19380443.
      Citations:    
    252. Dy GK, Hobday TJ, Nelson G, Windschitl HE, O'Connell MJ, Alberts SR, Goldberg RM, Nikcevich DA, Sargent DJ. Long-term survivors of metastatic colorectal cancer treated with systemic chemotherapy alone: a North Central Cancer Treatment Group review of 3811 patients, N0144. Clin Colorectal Cancer. 2009 Apr; 8(2):88-93. PMID: 19739269.
      Citations:    
    253. Bertagnolli MM, Warren RS, Niedzwiecki D, Mueller E, Compton CC, Redston M, Hall M, Hahn HP, Jewell SD, Mayer RJ, Goldberg RM, Saltz LB, Loda M. p27Kip1 in stage III colon cancer: implications for outcome following adjuvant chemotherapy in cancer and leukemia group B protocol 89803. Clin Cancer Res. 2009 Mar 15; 15(6):2116-22. PMID: 19276255.
      Citations:    
    254. Bertagnolli MM, Niedzwiecki D, Compton CC, Hahn HP, Hall M, Damas B, Jewell SD, Mayer RJ, Goldberg RM, Saltz LB, Warren RS, Redston M. Microsatellite instability predicts improved response to adjuvant therapy with irinotecan, fluorouracil, and leucovorin in stage III colon cancer: Cancer and Leukemia Group B Protocol 89803. J Clin Oncol. 2009 Apr 10; 27(11):1814-21. PMID: 19273709.
      Citations:    
    255. Sargent DJ, K?hne CH, Sanoff HK, Bot BM, Seymour MT, de Gramont A, Porschen R, Saltz LB, Rougier P, Tournigand C, Douillard JY, Stephens RJ, Grothey A, Goldberg RM. Pooled safety and efficacy analysis examining the effect of performance status on outcomes in nine first-line treatment trials using individual data from patients with metastatic colorectal cancer. J Clin Oncol. 2009 Apr 20; 27(12):1948-55. PMID: 19255311.
      Citations:    
    256. Dy GK, Hobday TJ, Nelson G, Windschitl HE, O'Connell MJ, Alberts SR, Goldberg RM, Nikcevich DA, Sargent DJ. Long-term survivors of metastatic colorectal cancer treated with systemic chemotherapy alone: a north central cancer treatment group review of 3811 patients, n0144. Clin Colorectal Cancer. 2009 Mar; 8(2):88-93. PMID: 19423501.
      Citations:    
    257. Shah U, O'Neil B, Allen J, Goldberg RM, Bernard S, Moore D, Venook AP, Morse MM. A Phase II Study of Long-Acting Octreotide in Patients With Advanced Hepatocellular Carcinoma and CLIP Score of 3 or Higher. Gastrointest Cancer Res. 2009 Mar; 3(2):45-8. PMID: 19461906.
      Citations:    
    258. Kuhn G, Goldberg R, Compton S. Tolerance for uncertainty, burnout, and satisfaction with the career of emergency medicine. Ann Emerg Med. 2009 Jul; 54(1):106-113.e6. PMID: 19201058.
      Citations:    
    259. Cmelak AJ, Goldberg RM. Infusion reactions associated with monoclonal antibodies in patients with solid tumors. Introduction. Oncology (Williston Park). 2009 Feb; 23(2 Suppl 1):5-6. PMID: 19385160.
      Citations:    
    260. Cmelak AJ, Lordick F, Borner M, Goldberg RM, Saif MW. Management of infusion reactions in clinical trials and beyond: the US and EU perspectives. Oncology (Williston Park). 2009 Feb; 23(2 Suppl 1):18-25. PMID: 19385163.
      Citations:    
    261. Wood WA, McCabe MS, Goldberg RM. Commentary: Disclosure in oncology -- to whom does the truth belong? Oncologist. 2009 Jan; 14(1):77-82. PMID: 19147691.
      Citations:    
    262. Sargent D, Sobrero A, Grothey A, O'Connell MJ, Buyse M, Andre T, Zheng Y, Green E, Labianca R, O'Callaghan C, Seitz JF, Francini G, Haller D, Yothers G, Goldberg R, de Gramont A. Evidence for cure by adjuvant therapy in colon cancer: observations based on individual patient data from 20,898 patients on 18 randomized trials. J Clin Oncol. 2009 Feb 20; 27(6):872-7. PMID: 19124803.
      Citations:    
    263. McWhinney SR, Goldberg RM, McLeod HL. Platinum neurotoxicity pharmacogenetics. Mol Cancer Ther. 2009 Jan; 8(1):10-6. PMID: 19139108.
      Citations:    
    264. Himelhoch S, McCarthy JF, Ganoczy D, Medoff D, Kilbourne A, Goldberg R, Dixon L, Blow FC. Understanding associations between serious mental illness and hepatitis C virus among veterans: a national multivariate analysis. Psychosomatics. 2009 Jan-Feb; 50(1):30-7. PMID: 19213970.
      Citations:    
    265. Fuchs CS, Goldberg RM, Sargent DJ, Meyerhardt JA, Wolpin BM, Green EM, Pitot HC, Pollak M. Plasma insulin-like growth factors, insulin-like binding protein-3, and outcome in metastatic colorectal cancer: results from intergroup trial N9741. Clin Cancer Res. 2008 Dec 15; 14(24):8263-9. PMID: 19073970.
      Citations:    
    266. Raftery L, Sanoff HK, Goldberg R. Colon cancer in older adults. Semin Oncol. 2008 Dec; 35(6):561-8. PMID: 19027460.
      Citations:    
    267. Davies JM, Goldberg RM. First-line therapeutic strategies in metastatic colorectal cancer. Oncology (Williston Park). 2008 Nov 30; 22(13):1470-9. PMID: 19133603.
      Citations:    
    268. O'Neil BH, Goldberg RM. What is the standard chemotherapy for colorectal cancer patients with resectable liver metastases? Nat Clin Pract Oncol. 2009 Jan; 6(1):14-6. PMID: 19002130.
      Citations:    
    269. Sanoff HK, Sargent DJ, Campbell ME, Morton RF, Fuchs CS, Ramanathan RK, Williamson SK, Findlay BP, Pitot HC, Goldberg RM. Five-year data and prognostic factor analysis of oxaliplatin and irinotecan combinations for advanced colorectal cancer: N9741. J Clin Oncol. 2008 Dec 10; 26(35):5721-7. PMID: 19001325.
      Citations:    
    270. O'Neil BH, Goldberg RM. Innovations in chemotherapy for metastatic colorectal cancer: an update of recent clinical trials. Oncologist. 2008 Oct; 13(10):1074-83. PMID: 18922828.
      Citations:    
    271. Shah U, Goldberg RM. Sequential versus combination therapy in the treatment of patients with advanced colorectal cancer. Clin Colorectal Cancer. 2008 Sep; 7(5):315-20. PMID: 18794063.
      Citations:    
    272. Chan JA, Meyerhardt JA, Niedzwiecki D, Hollis D, Saltz LB, Mayer RJ, Thomas J, Schaefer P, Whittom R, Hantel A, Goldberg RM, Warren RS, Bertagnolli M, Fuchs CS. Association of family history with cancer recurrence and survival among patients with stage III colon cancer. JAMA. 2008 Jun 04; 299(21):2515-23. PMID: 18523220.
      Citations:    
    273. French AJ, Sargent DJ, Burgart LJ, Foster NR, Kabat BF, Goldberg R, Shepherd L, Windschitl HE, Thibodeau SN. Prognostic significance of defective mismatch repair and BRAF V600E in patients with colon cancer. Clin Cancer Res. 2008 Jun 01; 14(11):3408-15. PMID: 18519771.
      Citations:    
    274. Meropol NJ, Niedzwiecki D, Shank B, Colacchio TA, Ellerton J, Valone F, Budinger S, Day JM, Hopkins J, Tepper J, Goldberg RM, Mayer RJ. Induction therapy for poor-prognosis anal canal carcinoma: a phase II study of the cancer and Leukemia Group B (CALGB 9281). J Clin Oncol. 2008 Jul 01; 26(19):3229-34. PMID: 18490648.
      Citations:    
    275. O'Connell MJ, Campbell ME, Goldberg RM, Grothey A, Seitz JF, Benedetti JK, Andr? T, Haller DG, Sargent DJ. Survival following recurrence in stage II and III colon cancer: findings from the ACCENT data set. J Clin Oncol. 2008 May 10; 26(14):2336-41. PMID: 18467725.
      Citations:    
    276. Stinchcombe TE, Socinski MA, Lee CB, Hayes DN, Moore DT, Goldberg RM, Dees EC. Phase I trial of nanoparticle albumin-bound paclitaxel in combination with gemcitabine in patients with thoracic malignancies. J Thorac Oncol. 2008 May; 3(5):521-6. PMID: 18449006.
      Citations:    
    277. Goldberg RM, Carrato A. Accomplishments in 2007 in the treatment of advanced colorectal cancer. Gastrointest Cancer Res. 2008 May; 2(3 Suppl):S19-24. PMID: 19352463.
      Citations:    
    278. Goldberg RM. As Federal Funding for Cancer is Cut, Researchers Struggle. Gastrointest Cancer Res. 2008 May; 2(3):165. PMID: 19259296.
      Citations:    
    279. K?hne CH, Folprecht G, Goldberg RM, Mitry E, Rougier P. Chemotherapy in elderly patients with colorectal cancer. Oncologist. 2008 Apr; 13(4):390-402. PMID: 18448553.
      Citations:    
    280. Tepper J, Krasna MJ, Niedzwiecki D, Hollis D, Reed CE, Goldberg R, Kiel K, Willett C, Sugarbaker D, Mayer R. Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781. J Clin Oncol. 2008 Mar 01; 26(7):1086-92. PMID: 18309943.
      Citations:    
    281. Grothey A, Hedrick EE, Mass RD, Sarkar S, Suzuki S, Ramanathan RK, Hurwitz HI, Goldberg RM, Sargent DJ. Response-independent survival benefit in metastatic colorectal cancer: a comparative analysis of N9741 and AVF2107. J Clin Oncol. 2008 Jan 10; 26(2):183-9. PMID: 18182660.
      Citations:    
    282. Yen-Revollo JL, Goldberg RM, McLeod HL. Can inhibiting dihydropyrimidine dehydrogenase limit hand-foot syndrome caused by fluoropyrimidines? Clin Cancer Res. 2008 Jan 01; 14(1):8-13. PMID: 18172246.
      Citations:    
    283. Shah U, Goldberg RM. Dealing With Discordance: Managing a Case Where the Patient Looks Better and the CT Scan Looks Worse. Gastrointest Cancer Res. 2008 Jan; 2(1):45-6. PMID: 19259322.
      Citations:    
    284. Posner MC, Niedzwiecki D, Venook AP, Hollis DR, Kindler HL, Martin EW, Schilsky RL, Goldberg RM, Mayer RJ. A phase II prospective multi-institutional trial of adjuvant active specific immunotherapy following curative resection of colorectal cancer hepatic metastases: cancer and leukemia group B study 89903. Ann Surg Oncol. 2008 Jan; 15(1):158-64. PMID: 18008108.
      Citations:    
    285. O'Neil BH, Buzkov? P, Farrah H, Kashatus D, Sanoff H, Goldberg RM, Baldwin AS, Funkhouser WK. Expression of nuclear factor-kappaB family proteins in hepatocellular carcinomas. Oncology. 2007; 72(1-2):97-104. PMID: 18025803.
      Citations:    
    286. Goldberg RM, Marshall JL, Ajani JA, Philip PA, O'Reilly EM, Venook AP. Section IV: Significance of Recent Study Results and Future Research Directions in Gastrointestinal Oncology. Gastrointest Cancer Res. 2007 Nov; 1(6 Suppl):S13-6. PMID: 19330058.
      Citations:    
    287. Sanoff HK, Goldberg RM, Pignone MP. A systematic review of the use of quality of life measures in colorectal cancer research with attention to outcomes in elderly patients. Clin Colorectal Cancer. 2007 Nov; 6(10):700-9. PMID: 18039423.
      Citations:    
    288. Goldberg RM, Marshall JL, Kachnic LA, Venook AP. Section I: essentials of ensuring excellence in cancer care. Gastrointest Cancer Res. 2007 Nov; 1(6 Suppl):S1-3. PMID: 19330057.
      Citations:    
    289. Sanoff HK, Goldberg RM. Colorectal cancer treatment in older patients. Gastrointest Cancer Res. 2007 Nov; 1(6):248-53. PMID: 19262903.
      Citations:    
    290. Sargent DJ, Patiyil S, Yothers G, Haller DG, Gray R, Benedetti J, Buyse M, Labianca R, Seitz JF, O'Callaghan CJ, Francini G, Grothey A, O'Connell M, Catalano PJ, Kerr D, Green E, Wieand HS, Goldberg RM, de Gramont A. End points for colon cancer adjuvant trials: observations and recommendations based on individual patient data from 20,898 patients enrolled onto 18 randomized trials from the ACCENT Group. J Clin Oncol. 2007 Oct 10; 25(29):4569-74. PMID: 17876008.
      Citations:    
    291. Hoskins JM, Goldberg RM, Qu P, Ibrahim JG, McLeod HL. UGT1A1*28 genotype and irinotecan-induced neutropenia: dose matters. J Natl Cancer Inst. 2007 Sep 05; 99(17):1290-5. PMID: 17728214.
      Citations:    
    292. O'Neil BH, Allen R, Spigel DR, Stinchcombe TE, Moore DT, Berlin JD, Goldberg RM. High incidence of cetuximab-related infusion reactions in Tennessee and North Carolina and the association with atopic history. J Clin Oncol. 2007 Aug 20; 25(24):3644-8. PMID: 17704414.
      Citations:    
    293. Allegra C, Blanke C, Buyse M, Goldberg R, Grothey A, Meropol NJ, Saltz L, Venook A, Yothers G, Sargent D. End points in advanced colon cancer clinical trials: a review and proposal. J Clin Oncol. 2007 Aug 20; 25(24):3572-5. PMID: 17704403.
      Citations:    
    294. Saltz LB, Niedzwiecki D, Hollis D, Goldberg RM, Hantel A, Thomas JP, Fields AL, Mayer RJ. Irinotecan fluorouracil plus leucovorin is not superior to fluorouracil plus leucovorin alone as adjuvant treatment for stage III colon cancer: results of CALGB 89803. J Clin Oncol. 2007 Aug 10; 25(23):3456-61. PMID: 17687149.
      Citations:    
    295. Dy GK, Krook JE, Green EM, Sargent DJ, Delaunoit T, Morton RF, Fuchs CS, Ramanathan RK, Williamson SK, Findlay BP, Pockaj BA, Sticca RP, Alberts SR, Pitot HC, Goldberg RM. Impact of complete response to chemotherapy on overall survival in advanced colorectal cancer: results from Intergroup N9741. J Clin Oncol. 2007 Aug 10; 25(23):3469-74. PMID: 17687151.
      Citations:    
    296. Ashley AC, Sargent DJ, Alberts SR, Grothey A, Campbell ME, Morton RF, Fuchs CS, Ramanathan RK, Williamson SK, Findlay BP, Pitot HC, Goldberg RM. Updated efficacy and toxicity analysis of irinotecan and oxaliplatin (IROX) : intergroup trial N9741 in first-line treatment of metastatic colorectal cancer. Cancer. 2007 Aug 01; 110(3):670-7. PMID: 17559146.
      Citations:    
    297. Hackman A, Brown C, Yang Y, Goldberg R, Kreyenbuhl J, Lucksted A, Wohlheiter K, Dixon L. Consumer satisfaction with inpatient psychiatric treatment among persons with severe mental illness. Community Ment Health J. 2007 Dec; 43(6):551-64. PMID: 17641972.
      Citations:    
    298. Marshall JL, Haller DG, de Gramont A, Hochster HS, Lenz HJ, Ajani JA, Goldberg RM. Adjuvant Therapy for Stage II and III Colon Cancer: Consensus Report of the International Society of Gastrointestinal Oncology. Gastrointest Cancer Res. 2007 Jul; 1(4):146-54. PMID: 19262703.
      Citations:    
    299. Alberts SR, Kim GP, Mahoney MR, Gornet MK, Rubin J, Ames M, Goetz MP, Weinshilboum RM, Nicol SJ, Goldberg RM. Pemetrexed and oxaliplatin for metastatic colorectal cancer: results of a phase I Mayo Cancer Center Research Consortium trial, MC0248. Clin Colorectal Cancer. 2007 Jul; 6(8):572-7. PMID: 17681103.
      Citations:    
    300. Bendell J, Goldberg RM. Targeted agents in the treatment of pancreatic cancer: history and lessons learned. Curr Opin Oncol. 2007 Jul; 19(4):390-5. PMID: 17545806.
      Citations:    
    301. Sanoff HK, Bleiberg H, Goldberg RM. Managing older patients with colorectal cancer. J Clin Oncol. 2007 May 10; 25(14):1891-7. PMID: 17488988.
      Citations:    
    302. O'Neil B, Goldberg RM. On the state of the art of adjuvant chemotherapy for colon cancer. Gastrointest Cancer Res. 2007 May; 1(3):115-7. PMID: 19262717.
      Citations:    
    303. O'Neil BH, Goldberg RM. Should gemcitabine be used as adjuvant chemotherapy in patients with resectable pancreatic cancer? Nat Clin Pract Gastroenterol Hepatol. 2007 Jul; 4(7):362-3. PMID: 17471277.
      Citations:    
    304. Venook AP, Blanke CD, Niedzwiecki D, Lenz HJ, Taylor JR, Hollis DR, Sutherland S, Goldberg RM. Revisiting the Cancer and Leukemia Group B/Southwest Oncology Group 80405 Trial: a phase III trial of chemotherapy and biologic agents for patients with untreated advanced colorectal adenocarcinoma. Clin Colorectal Cancer. 2007 May; 6(7):536-8. PMID: 17553204.
      Citations:    
    305. Sinicrope FA, Rego RL, Garrity-Park MM, Foster NR, Sargent DJ, Goldberg RM, Wiesenfeld M, Witzig TE, Thibodeau SN, Burgart LJ. Alterations in cell proliferation and apoptosis in colon cancers with microsatellite instability. Int J Cancer. 2007 Mar 15; 120(6):1232-8. PMID: 17187355.
      Citations:    
    306. Dixon L, Medoff DR, Wohlheiter K, DiClemente C, Goldberg R, Kreyenbuhl J, Adams C, Lucksted A, Davin C. Correlates of severity of smoking among persons with severe mental illness. Am J Addict. 2007 Mar-Apr; 16(2):101-10. PMID: 17453611.
      Citations:    
    307. Stinchcombe TE, Socinski MA, Walko CM, O'Neil BH, Collichio FA, Ivanova A, Mu H, Hawkins MJ, Goldberg RM, Lindley C, Dees EC. Phase I and pharmacokinetic trial of carboplatin and albumin-bound paclitaxel, ABI-007 (Abraxane) on three treatment schedules in patients with solid tumors. Cancer Chemother Pharmacol. 2007 Oct; 60(5):759-66. PMID: 17285317.
      Citations:    
    308. Skelton MR, Goldberg RM, O'Neil BH. A case of oxaliplatin-related posterior reversible encephalopathy syndrome. Clin Colorectal Cancer. 2007 Jan; 6(5):386-8. PMID: 17311705.
      Citations:    
    309. Gill S, Blackstock AW, Goldberg RM. Colorectal cancer. Mayo Clin Proc. 2007 Jan; 82(1):114-29. PMID: 17285793.
      Citations:    
    310. Goldberg RM, Rothenberg ML, Van Cutsem E, Benson AB, Blanke CD, Diasio RB, Grothey A, Lenz HJ, Meropol NJ, Ramanathan RK, Becerra CH, Wickham R, Armstrong D, Viele C. The continuum of care: a paradigm for the management of metastatic colorectal cancer. Oncologist. 2007 Jan; 12(1):38-50. PMID: 17227899.
      Citations:    
    311. Goldberg RM. Which strategies will lead to progress in the management of colorectal cancer? Gastrointest Cancer Res. 2007; 1(4 Suppl 2):S33-6. PMID: 19360145.
      Citations:    
    312. Goldberg RM. Therapy for metastatic colorectal cancer. Oncologist. 2006 Oct; 11(9):981-7. PMID: 17030638.
      Citations:    
    313. Patel DD, Goldberg RM. Cetuximab-associated infusion reactions: pathology and management. Oncology (Williston Park). 2006 Oct; 20(11):1373-82; discussion 1382, 1392-4, 1397. PMID: 17112000.
      Citations:    
    314. Goel A, Nagasaka T, Arnold CN, Inoue T, Hamilton C, Niedzwiecki D, Compton C, Mayer RJ, Goldberg R, Bertagnolli MM, Boland CR. The CpG island methylator phenotype and chromosomal instability are inversely correlated in sporadic colorectal cancer. Gastroenterology. 2007 Jan; 132(1):127-38. PMID: 17087942.
      Citations:    
    315. Sinicrope FA, Rego RL, Halling KC, Foster N, Sargent DJ, La Plant B, French AJ, Laurie JA, Goldberg RM, Thibodeau SN, Witzig TE. Prognostic impact of microsatellite instability and DNA ploidy in human colon carcinoma patients. Gastroenterology. 2006 Sep; 131(3):729-37. PMID: 16952542.
      Citations:    
    316. Goldberg RM, Tabah-Fisch I, Bleiberg H, de Gramont A, Tournigand C, Andre T, Rothenberg ML, Green E, Sargent DJ. Pooled analysis of safety and efficacy of oxaliplatin plus fluorouracil/leucovorin administered bimonthly in elderly patients with colorectal cancer. J Clin Oncol. 2006 Sep 01; 24(25):4085-91. PMID: 16943526.
      Citations:    
    317. Goldberg RM, Hurwitz HI, Fuchs CS. The role of targeted therapy in the treatment of colorectal cancer. Clin Adv Hematol Oncol. 2006 Aug; 4(8 Suppl 17):1-10; quiz 11-2. PMID: 17139241.
      Citations:    
    318. Goldberg RM, Sargent DJ, Morton RF, Fuchs CS, Ramanathan RK, Williamson SK, Findlay BP, Pitot HC, Alberts S. Randomized controlled trial of reduced-dose bolus fluorouracil plus leucovorin and irinotecan or infused fluorouracil plus leucovorin and oxaliplatin in patients with previously untreated metastatic colorectal cancer: a North American Intergroup Trial. J Clin Oncol. 2006 Jul 20; 24(21):3347-53. PMID: 16849748.
      Citations:    
    319. Schaaf LJ, Hammond LA, Tipping SJ, Goldberg RM, Goel R, Kuhn JG, Miller LL, Compton LD, Cisar LA, Elfring GL, Gruia G, McGovren JP, Pirotta N, Yin D, Sharma A, Duncan BA, Rothenberg ML. Phase 1 and pharmacokinetic study of intravenous irinotecan in refractory solid tumor patients with hepatic dysfunction. Clin Cancer Res. 2006 Jun 15; 12(12):3782-91. PMID: 16778106.
      Citations:    
    320. Goldberg RM, Niedzwiecki D, Bertagnolli M, Blackstock AW, Tepper JE, Mayer RJ. Cancer and leukemia group B gastrointestinal cancer committee. Clin Cancer Res. 2006 Jun 01; 12(11 Pt 2):3589s-95s. PMID: 16740790.
      Citations:    
    321. Sinicrope FA, Rego RL, Halling KC, Foster NR, Sargent DJ, La Plant B, French AJ, Allegra CJ, Laurie JA, Goldberg RM, Witzig TE, Thibodeau SN. Thymidylate synthase expression in colon carcinomas with microsatellite instability. Clin Cancer Res. 2006 May 01; 12(9):2738-44. PMID: 16675565.
      Citations:    
    322. Ryan DP, Niedzwiecki D, Hollis D, Mediema BE, Wadler S, Tepper JE, Goldberg RM, Mayer RJ. Phase I/II study of preoperative oxaliplatin, fluorouracil, and external-beam radiation therapy in patients with locally advanced rectal cancer: Cancer and Leukemia Group B 89901. J Clin Oncol. 2006 Jun 01; 24(16):2557-62. PMID: 16636336.
      Citations:    
    323. Beaven AW, Goldberg RM. Adjuvant therapy for colorectal cancer: yesterday, today, and tomorrow. Oncology (Williston Park). 2006 Apr; 20(5):461-9; discussion 469-70, 473-5. PMID: 16739745.
      Citations:    
    324. Delaunoit T, Limburg PJ, Goldberg RM, Lymp JF, Loftus EV. Colorectal cancer prognosis among patients with inflammatory bowel disease. Clin Gastroenterol Hepatol. 2006 Mar; 4(3):335-42. PMID: 16527697.
      Citations:    
    325. Mahoney MR, Sargent DJ, O'Connell MJ, Goldberg RM, Schaefer P, Buckner JC. Dealing with a deluge of data: an assessment of adverse event data on North Central Cancer Treatment Group trials. J Clin Oncol. 2005 Dec 20; 23(36):9275-81. PMID: 16361625.
      Citations:    
    326. Goldberg RM. Intensive surveillance after stage II or III colorectal cancer: is it worth it? J Clin Oncol. 2006 Jan 20; 24(3):330-1. PMID: 16365175.
      Citations:    
    327. Goldberg RM, Hurwitz HI, Fuchs CS. Angiogenesis inhibition in the treatment of colorectal cancer Part 3 of a 3-part series: targeting VEGF--current and future research directions. Clin Adv Hematol Oncol. 2005 Dec; 3(12):1-10; quiz 11. PMID: 16555433.
      Citations:    
    328. Hillner BE, Schrag D, Sargent DJ, Fuchs CS, Goldberg RM. Cost-effectiveness projections of oxaliplatin and infusional fluorouracil versus irinotecan and bolus fluorouracil in first-line therapy for metastatic colorectal carcinoma. Cancer. 2005 Nov 01; 104(9):1871-84. PMID: 16177989.
      Citations:    
    329. Venook AP, Blanke CD, Niedzwiecki D, Lenz HJ, Taylor JR, Hollis DR, Sutherland S, Goldberg RM. Cancer and Leukemia Group B/Southwest Oncology Group trial 80405: a phase III trial of chemotherapy and biologics for patients with untreated advanced colorectal adenocarcinoma. Clin Colorectal Cancer. 2005 Nov; 5(4):292-4. PMID: 16356309.
      Citations:    
    330. Sargent DJ, Wieand HS, Haller DG, Gray R, Benedetti JK, Buyse M, Labianca R, Seitz JF, O'Callaghan CJ, Francini G, Grothey A, O'Connell M, Catalano PJ, Blanke CD, Kerr D, Green E, Wolmark N, Andre T, Goldberg RM, De Gramont A. Disease-free survival versus overall survival as a primary end point for adjuvant colon cancer studies: individual patient data from 20,898 patients on 18 randomized trials. J Clin Oncol. 2005 Dec 01; 23(34):8664-70. PMID: 16260700.
      Citations:    
    331. Alberts SR, Horvath WL, Sternfeld WC, Goldberg RM, Mahoney MR, Dakhil SR, Levitt R, Rowland K, Nair S, Sargent DJ, Donohue JH. Oxaliplatin, fluorouracil, and leucovorin for patients with unresectable liver-only metastases from colorectal cancer: a North Central Cancer Treatment Group phase II study. J Clin Oncol. 2005 Dec 20; 23(36):9243-9. PMID: 16230673.
      Citations:    
    332. Gill S, Lindor NM, Burgart LJ, Smalley R, Leontovich O, French AJ, Goldberg RM, Sargent DJ, Jass JR, Hopper JL, Jenkins MA, Young J, Barker MA, Walsh MD, Ruszkiewicz AR, Thibodeau SN. Isolated loss of PMS2 expression in colorectal cancers: frequency, patient age, and familial aggregation. Clin Cancer Res. 2005 Sep 15; 11(18):6466-71. PMID: 16166421.
      Citations:    
    333. Kelly H, Goldberg RM. Systemic therapy for metastatic colorectal cancer: current options, current evidence. J Clin Oncol. 2005 Jul 10; 23(20):4553-60. PMID: 16002847.
      Citations:    
    334. Goldberg RM. Lessons learned from the edrecolomab story: how a checkered past became a checkered flag for monoclonal antibodies in colorectal cancer therapy. Onkologie. 2005 Jun; 28(6-7):311-2. PMID: 15933417.
      Citations:    
    335. Gill S, Goldberg RM. Duration of adjuvant therapy for colorectal cancer: are we overtreating our patients? Nat Clin Pract Oncol. 2005 Jun; 2(6):276-7. PMID: 16264965.
      Citations:    
    336. Meyerhardt JA, Sloan JA, Sargent DJ, Goldberg RM, Pollak M, Morton RF, Ramanathan RK, Williamson SK, Findlay BP, Fuchs CS. Associations between plasma insulin-like growth factor proteins and C-peptide and quality of life in patients with metastatic colorectal cancer. Cancer Epidemiol Biomarkers Prev. 2005 Jun; 14(6):1402-10. PMID: 15941948.
      Citations:    
    337. Goldberg RM. Cetuximab. Nat Rev Drug Discov. 2005 May; Suppl:S10-1. PMID: 15962524.
      Citations:    
    338. Lindor NM, Rabe K, Petersen GM, Haile R, Casey G, Baron J, Gallinger S, Bapat B, Aronson M, Hopper J, Jass J, LeMarchand L, Grove J, Potter J, Newcomb P, Terdiman JP, Conrad P, Moslein G, Goldberg R, Ziogas A, Anton-Culver H, de Andrade M, Siegmund K, Thibodeau SN, Boardman LA, Seminara D. Lower cancer incidence in Amsterdam-I criteria families without mismatch repair deficiency: familial colorectal cancer type X. JAMA. 2005 Apr 27; 293(16):1979-85. PMID: 15855431.
      Citations:    
    339. Poplin EA, Benedetti JK, Estes NC, Haller DG, Mayer RJ, Goldberg RM, Weiss GR, Rivkin SE, Macdonald JS. Phase III Southwest Oncology Group 9415/Intergroup 0153 randomized trial of fluorouracil, leucovorin, and levamisole versus fluorouracil continuous infusion and levamisole for adjuvant treatment of stage III and high-risk stage II colon cancer. J Clin Oncol. 2005 Mar 20; 23(9):1819-25. PMID: 15774775.
      Citations:    
    340. Dy GK, Suri A, Reid JM, Sloan JA, Pitot HC, Alberts SR, Goldberg RM, Atherton PJ, Hanson LJ, Burch PA, Rubin J, Erlichman C, Adjei AA. A phase IB study of the pharmacokinetics of gemcitabine and pemetrexed, when administered in rapid sequence to patients with advanced solid tumors. Cancer Chemother Pharmacol. 2005 Jun; 55(6):522-30. PMID: 15754203.
      Citations:    
    341. O'Neil BH, Goldberg RM. Chemotherapy for advanced colorectal cancer: let's not forget how we got here (until we really can). Semin Oncol. 2005 Feb; 32(1):35-42. PMID: 15726504.
      Citations:    
    342. Tepper JE, Goldberg RM. An embarrassment of riches: neoadjuvant therapy of rectal cancer. J Clin Oncol. 2005 Mar 01; 23(7):1339-41. PMID: 15684316.
      Citations:    
    343. D'Andre S, Sargent DJ, Cha SS, Buroker TR, Kugler JW, Goldberg RM, O'Connell MJ, Poon MA. 5-Fluorouracil-based chemotherapy for advanced colorectal cancer in elderly patients: a north central cancer treatment group study. Clin Colorectal Cancer. 2005 Jan; 4(5):325-31. PMID: 15663836.
      Citations:    
    344. Goldberg RM. Advances in the treatment of metastatic colorectal cancer. Oncologist. 2005; 10 Suppl 3:40-8. PMID: 16368870.
      Citations:    
    345. Delaunoit T, Goldberg RM, Sargent DJ, Morton RF, Fuchs CS, Findlay BP, Thomas SP, Salim M, Schaefer PL, Stella PJ, Green E, Mailliard JA. Mortality associated with daily bolus 5-fluorouracil/leucovorin administered in combination with either irinotecan or oxaliplatin: results from Intergroup Trial N9741. Cancer. 2004 Nov 15; 101(10):2170-6. PMID: 15470715.
      Citations:    
    346. Goldberg RM, Venook AP, Schilsky RL. Cetuximab in the treatment of colorectal cancer. Clin Adv Hematol Oncol. 2004 Nov; 2(11):1-10; quiz 11-12. PMID: 16170891.
      Citations:    
    347. Penland SK, Goldberg RM. Combining anti-VEGF approaches with oxaliplatin in advanced colorectal cancer. Clin Colorectal Cancer. 2004 Oct; 4 Suppl 2:S74-80. PMID: 15479483.
      Citations:    
    348. Grothey A, Goldberg RM. A review of oxaliplatin and its clinical use in colorectal cancer. Expert Opin Pharmacother. 2004 Oct; 5(10):2159-70. PMID: 15461551.
      Citations:    
    349. Goldberg RM, Gill S. Recent phase III trials of fluorouracil, irinotecan, and oxaliplatin as chemotherapy for metastatic colorectal cancer. Cancer Chemother Pharmacol. 2004 Sep; 54 Suppl 1:S57-64. PMID: 15309516.
      Citations:    
    350. Martenson JA, Willett CG, Sargent DJ, Mailliard JA, Donohue JH, Gunderson LL, Thomas CR, Fisher B, Benson AB, Myerson R, Goldberg RM. Phase III study of adjuvant chemotherapy and radiation therapy compared with chemotherapy alone in the surgical adjuvant treatment of colon cancer: results of intergroup protocol 0130. J Clin Oncol. 2004 Aug 15; 22(16):3277-83. PMID: 15249584.
      Citations:    
    351. Goldberg R, Hillberg R, Reinecker L, Goldstein R. Evaluation of patients with severe pulmonary disease before and after pulmonary rehabilitation. Disabil Rehabil. 2004 Jun 03; 26(11):641-8. PMID: 15204502.
      Citations:    
    352. Goldberg RM. Current approaches to first-line treatment of advanced colorectal cancer. Clin Colorectal Cancer. 2004 Jun; 4 Suppl 1:S9-15. PMID: 15212700.
      Citations:    
    353. Lindor NM, Sloan J, Goldberg R, Bowen D, Nigon S, Roche A, Petersen G, Thibodeau SN, Burgart L, Leontovich O, Morlan BW. Colorectal tumour microsatellite instability test results: perspectives from patients. Hered Cancer Clin Pract. 2004 May 15; 2(2):69-75. PMID: 20233473.
      Citations:    
    354. Garrity MM, Burgart LJ, Mahoney MR, Windschitl HE, Salim M, Wiesenfeld M, Krook JE, Michalak JC, Goldberg RM, O'Connell MJ, Furth AF, Sargent DJ, Murphy LM, Hill E, Riehle DL, Meyers CH, Witzig TE. Prognostic value of proliferation, apoptosis, defective DNA mismatch repair, and p53 overexpression in patients with resected Dukes' B2 or C colon cancer: a North Central Cancer Treatment Group Study. J Clin Oncol. 2004 May 01; 22(9):1572-82. PMID: 15117979.
      Citations:    
    355. Penland SK, Goldberg RM. Current strategies in previously untreated advanced colorectal cancer. Oncology (Williston Park). 2004 May; 18(6):715-22, 727; discussion 727-9. PMID: 15214592.
      Citations:    
    356. Gunderson LL, Sargent DJ, Tepper JE, Wolmark N, O'Connell MJ, Begovic M, Allmer C, Colangelo L, Smalley SR, Haller DG, Martenson JA, Mayer RJ, Rich TA, Ajani JA, MacDonald JS, Willett CG, Goldberg RM. Impact of T and N stage and treatment on survival and relapse in adjuvant rectal cancer: a pooled analysis. J Clin Oncol. 2004 May 15; 22(10):1785-96. PMID: 15067027.
      Citations:    
    357. Gill S, Loprinzi CL, Sargent DJ, Thom? SD, Alberts SR, Haller DG, Benedetti J, Francini G, Shepherd LE, Francois Seitz J, Labianca R, Chen W, Cha SS, Heldebrant MP, Goldberg RM. Pooled analysis of fluorouracil-based adjuvant therapy for stage II and III colon cancer: who benefits and by how much? J Clin Oncol. 2004 May 15; 22(10):1797-806. PMID: 15067028.
      Citations:    
    358. Grothey A, Sargent D, Goldberg RM, Schmoll HJ. Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment. J Clin Oncol. 2004 Apr 01; 22(7):1209-14. PMID: 15051767.
      Citations:    
    359. Gill S, Goldberg RM. First-line treatment strategies to improve survival in patients with advanced colorectal cancer. Drugs. 2004; 64(1):27-44. PMID: 14723557.
      Citations:    
    360. Goldberg RM, Sargent DJ, Morton RF, Fuchs CS, Ramanathan RK, Williamson SK, Findlay BP, Pitot HC, Alberts SR. A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol. 2004 Jan 01; 22(1):23-30. PMID: 14665611.
      Citations:    
    361. O'Neil BH, Goldberg RM. Novel chemotherapeutic and targeted agents in metastatic colorectal cancer: the time has arrived. Expert Opin Investig Drugs. 2003 Dec; 12(12):1939-49. PMID: 14640938.
      Citations:    
    362. Gill S, Thomas RR, Goldberg RM. New targeted therapies in gastrointestinal cancers. Curr Treat Options Oncol. 2003 Oct; 4(5):393-403. PMID: 12941199.
      Citations:    
    363. Goetz MP, Erlichman C, Windebank AJ, Reid JM, Sloan JA, Atherton P, Adjei AA, Rubin J, Pitot H, Galanis E, Ames MM, Goldberg RM. Phase I and pharmacokinetic study of two different schedules of oxaliplatin, irinotecan, Fluorouracil, and leucovorin in patients with solid tumors. J Clin Oncol. 2003 Oct 15; 21(20):3761-9. PMID: 12963697.
      Citations:    
    364. Ribic CM, Sargent DJ, Moore MJ, Thibodeau SN, French AJ, Goldberg RM, Hamilton SR, Laurent-Puig P, Gryfe R, Shepherd LE, Tu D, Redston M, Gallinger S. Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer. N Engl J Med. 2003 Jul 17; 349(3):247-57. PMID: 12867608.
      Citations:    
    365. Adjei AA, Croghan GA, Erlichman C, Marks RS, Reid JM, Sloan JA, Pitot HC, Alberts SR, Goldberg RM, Hanson LJ, Bruzek LM, Atherton P, Thibault A, Palmer PA, Kaufmann SH. A Phase I trial of the farnesyl protein transferase inhibitor R115777 in combination with gemcitabine and cisplatin in patients with advanced cancer. Clin Cancer Res. 2003 Jul; 9(7):2520-6. PMID: 12855626.
      Citations:    
    366. Benson AB, Goldberg RM. Optimal use of the combination of irinotecan and 5-fluorouracil. Semin Oncol. 2003 Jun; 30(3 Suppl 6):68-77. PMID: 12802797.
      Citations:    
    367. Gill S, Goldberg RM. New developments in therapy for colorectal cancer. Curr Oncol Rep. 2003 May; 5(3):183-91. PMID: 12667415.
      Citations:    
    368. Martenson JA, Vigliotti AP, Pitot HC, Geeraerts LH, Sargent DJ, Haddock MG, Ghosh C, Keppen MD, Fitch TR, Goldberg RM. A phase I study of radiation therapy and twice-weekly gemcitabine and cisplatin in patients with locally advanced pancreatic cancer. Int J Radiat Oncol Biol Phys. 2003 Apr 01; 55(5):1305-10. PMID: 12654442.
      Citations:    
    369. Kakar S, Burgart LJ, Thibodeau SN, Rabe KG, Petersen GM, Goldberg RM, Lindor NM. Frequency of loss of hMLH1 expression in colorectal carcinoma increases with advancing age. Cancer. 2003 Mar 15; 97(6):1421-7. PMID: 12627505.
      Citations:    
    370. Goldberg RM. Evolving therapy and management of metastatic colon cancer. Clin Adv Hematol Oncol. 2003 Mar; 1(3):159-60. PMID: 16224396.
      Citations:    
    371. Adjei AA, Dy GK, Erlichman C, Reid JM, Sloan JA, Pitot HC, Alberts SR, Goldberg RM, Hanson LJ, Atherton PJ, Watanabe T, Geary RS, Holmlund J, Dorr FA. A phase I trial of ISIS 2503, an antisense inhibitor of H-ras, in combination with gemcitabine in patients with advanced cancer. Clin Cancer Res. 2003 Jan; 9(1):115-23. PMID: 12538459.
      Citations:    
    372. Goldberg RM, Sargent DJ, Morton RF, Mahoney MR, Krook JE, O'Connell MJ. Early detection of toxicity and adjustment of ongoing clinical trials: the history and performance of the North Central Cancer Treatment Group's real-time toxicity monitoring program. J Clin Oncol. 2002 Dec 01; 20(23):4591-6. PMID: 12454117.
      Citations:    
    373. Hobday TJ, Kugler JW, Mahoney MR, Sargent DJ, Sloan JA, Fitch TR, Krook JE, O'Connell MJ, Mailliard JA, Tirona MT, Tschetter LK, Cobau CD, Goldberg RM. Efficacy and quality-of-life data are related in a phase II trial of oral chemotherapy in previously untreated patients with metastatic colorectal carcinoma. J Clin Oncol. 2002 Dec 01; 20(23):4574-80. PMID: 12454115.
      Citations:    
    374. Hobday TJ, Goldberg RM. Perspectives on the role of sequential or combination chemotherapy for first-line and salvage therapy in advanced colorectal cancer. Clin Colorectal Cancer. 2002 Nov; 2(3):161-9. PMID: 12482332.
      Citations:    
    375. Gunderson LL, Sargent DJ, Tepper JE, O'Connell MJ, Allmer C, Smalley SR, Martenson JA, Haller DG, Mayer RJ, Rich TA, Ajani JA, Macdonald JS, Goldberg RM. Impact of T and N substage on survival and disease relapse in adjuvant rectal cancer: a pooled analysis. Int J Radiat Oncol Biol Phys. 2002 Oct 01; 54(2):386-96. PMID: 12243812.
      Citations:    
    376. Adjei AA, Reid JM, Erlichman C, Sloan JA, Pitot HC, Alberts SR, Goldberg RM, Hanson LJ, Ruben S, Boemer SA, Atherton P, Ames MM, Kaufmann SH. A phase I and pharmacologic study of pyrazoloacridine (NSC 366140) and carboplatin in patients with advanced cancer. Invest New Drugs. 2002 Aug; 20(3):297-304. PMID: 12201492.
      Citations:    
    377. Goldberg RM. N9741: a phase III study comparing irinotecan to oxaliplatin-containing regimens in advanced colorectal cancer. Clin Colorectal Cancer. 2002 Aug; 2(2):81. PMID: 12453321.
      Citations:    
    378. Allegra CJ, Parr AL, Wold LE, Mahoney MR, Sargent DJ, Johnston P, Klein P, Behan K, O'Connell MJ, Levitt R, Kugler JW, Tria Tirona M, Goldberg RM. Investigation of the prognostic and predictive value of thymidylate synthase, p53, and Ki-67 in patients with locally advanced colon cancer. J Clin Oncol. 2002 Apr 01; 20(7):1735-43. PMID: 11919229.
      Citations:    
    379. Adjei AA, Reid JM, Diasio RB, Sloan JA, Smith DA, Rubin J, Pitot HC, Alberts SR, Goldberg RM, Hanson LJ, Atherton P, Ames MM, Erlichman C. Comparative pharmacokinetic study of continuous venous infusion fluorouracil and oral fluorouracil with eniluracil in patients with advanced solid tumors. J Clin Oncol. 2002 Mar 15; 20(6):1683-91. PMID: 11896120.
      Citations:    
    380. Sloan JA, Goldberg RM, Sargent DJ, Vargas-Chanes D, Nair S, Cha SS, Novotny PJ, Poon MA, O'Connell MJ, Loprinzi CL. Women experience greater toxicity with fluorouracil-based chemotherapy for colorectal cancer. J Clin Oncol. 2002 Mar 15; 20(6):1491-8. PMID: 11896096.
      Citations:    
    381. Goldberg RM, Kuhn G, Andrew LB, Thomas HA. Coping with medical mistakes and errors in judgment. Ann Emerg Med. 2002 Mar; 39(3):287-92. PMID: 11867981.
      Citations:    
    382. Pitot HC, Reid JM, Sloan JA, Ames MM, Adjei AA, Rubin J, Bagniewski PG, Atherton P, Rayson D, Goldberg RM, Erlichman C. A Phase I study of bizelesin (NSC 615291) in patients with advanced solid tumors. Clin Cancer Res. 2002 Mar; 8(3):712-7. PMID: 11895900.
      Citations:    
    383. Lindor NM, Burgart LJ, Leontovich O, Goldberg RM, Cunningham JM, Sargent DJ, Walsh-Vockley C, Petersen GM, Walsh MD, Leggett BA, Young JP, Barker MA, Jass JR, Hopper J, Gallinger S, Bapat B, Redston M, Thibodeau SN. Immunohistochemistry versus microsatellite instability testing in phenotyping colorectal tumors. J Clin Oncol. 2002 Feb 15; 20(4):1043-8. PMID: 11844828.
      Citations:    
    384. Alberts SR, Fishkin PA, Burgart LJ, Cera PJ, Mahoney MR, Morton RF, Johnson PA, Nair S, Goldberg RM. CPT-11 for bile-duct and gallbladder carcinoma: a phase II North Central Cancer Treatment Group (NCCTG) study. Int J Gastrointest Cancer. 2002; 32(2-3):107-14. PMID: 12794246.
      Citations:    
    385. Jatoi A, Tirona MT, Cha SS, Alberts SR, Rowland KM, Morton RF, Nair S, Kardinal CG, Stella PJ, Mailliard JA, Sargen D, Goldberg RM. A phase II trial of docetaxel and CPT-11 in patients with metastatic adenocarcinoma of the esophagus, gastroesophageal junction, and gastric cardia. Int J Gastrointest Cancer. 2002; 32(2-3):115-23. PMID: 12794247.
      Citations:    
    386. Elder JH, Goldberg RM. Ecological statistics of Gestalt laws for the perceptual organization of contours. J Vis. 2002; 2(4):324-53. PMID: 12678582.
      Citations:    
    387. Lloyd RV, Schroeder G, Bauman MD, Krook JE, Jin L, Goldberg RM, Farr GH. Prevalence and Prognostic Significance of Neuroendocrine Differentiation in Colorectal Carcinomas. Endocr Pathol. 1998; 9(1):35-42. PMID: 12114660.
      Citations:    
    Goldberg's Networks
    Click the
    Explore
    buttons for more information and interactive visualizations!
    Concepts (702)
    Explore
    _
    Co-Authors (8)
    Explore
    _
    Similar People (60)
    Explore
    _
    Same Department Expand Description
    Explore
    _